{"protocolSection":{"identificationModule":{"nctId":"NCT03621670","orgStudyIdInfo":{"id":"205239"},"secondaryIdInfos":[{"id":"2016-003268-37","type":"EUDRACT_NUMBER"},{"id":"V72_57","type":"OTHER","domain":"Novartis"},{"id":"2016","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2016"}],"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","officialTitle":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants"},"statusModule":{"statusVerifiedDate":"2026-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-07-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-12-27","type":"ACTUAL"},"completionDateStruct":{"date":"2024-12-27","type":"ACTUAL"},"studyFirstSubmitDate":"2018-07-10","studyFirstSubmitQcDate":"2018-08-03","studyFirstPostDateStruct":{"date":"2018-08-08","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-12-23","resultsFirstSubmitQcDate":"2026-02-09","resultsFirstPostDateStruct":{"date":"2026-02-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-07-28","lastUpdatePostDateStruct":{"date":"2026-08-20","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recommended routine infant vaccinesv(RIV).","detailedDescription":"This study is divided into three timepoints:\n\nEpoch 1 - Primary: Day 1 to Day 301 Epoch 2 - Secondary: Day 301 to Day 331 Epoch 3 - Safety follow-up: Day 331 to the end of the study (Day 481 or Day 661). For participants who have not yet reached the 6-month safety follow-up after their last dose at the time Protocol Amendment 7 takes effect, visit 7 takes place on Day 481.\n\nIn addition to receiving the study vaccines, infants also receive non-study vaccines such as Diphtheria, tetanus toxoids and acellular pertussis adsorbed vaccine (DTPa, Infanrix) and Haemophilus influenzae type b Conjugate Vaccine (Hib, Hiberix) to minimize disruption to the standard infant vaccination schedule caused by participation in this study.\n\nParticipants receive rMenB+OMV NZ (Bexsero) concomitantly with PCV13 (Prevnar13) and other routine infant vaccines (Pediarix, Hiberix, Rotarix, M-M-R II, Varivax) at 2, 4, 6, and 12 months of age. Participants who have received three PCV13 doses before 12 months of age but have not yet received their fourth booster dose receive either PCV13 or PCV20 at 12 months of age (Visit 5)."},"conditionsModule":{"conditions":["Infections, Meningococcal"],"keywords":["Meningitis","Immune response","Sufficiency","Neisseria meningitides","Bexsero"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"Observer-blind study Data are collected in an observer-blind manner. Observer-blind means that throughout the study, the participant/parent/caregiver, as well as site and sponsor personnel involved in the clinical evaluation of participants, are blinded, while other study personnel are aware of the treatment assignment. To maintain this blinding, authorized medical personnel prepare and administer the vaccines but do not participate in any clinical evaluation assays or procedures.\n\nSerological data that could lead to unblinding of the study groups are not available during the study to any investigator or personnel involved in the clinical conduct of the study. The laboratory responsible for the testing is blinded to the treatment, participant, and visit number, and uses coded identifiers to link the participant, visit, and study to each sample.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1196,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"MenB+PCV Group","type":"EXPERIMENTAL","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301.","interventionNames":["Biological: Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)","Biological: Prevnar13","Biological: Pediarix","Biological: Hiberix","Biological: Rotarix","Biological: M-M-R II","Biological: Varivax","Biological: Prevnar 20"]},{"label":"Placebo+PCV Group","type":"PLACEBO_COMPARATOR","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301.","interventionNames":["Biological: Prevnar13","Biological: Pediarix","Biological: Hiberix","Biological: Rotarix","Biological: M-M-R II","Biological: Varivax","Biological: Placebo (saline water)","Biological: Prevnar 20"]}],"interventions":[{"type":"BIOLOGICAL","name":"Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)","description":"Bexsero was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.","armGroupLabels":["MenB+PCV Group"]},{"type":"BIOLOGICAL","name":"Prevnar13","description":"Prevnar13 (PCV13) was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.","armGroupLabels":["MenB+PCV Group","Placebo+PCV Group"]},{"type":"BIOLOGICAL","name":"Pediarix","description":"Pediarix (DTPa-HBV-IPV) was administered intramuscularly on Day 1, Day 61, and Day 121.","armGroupLabels":["MenB+PCV Group","Placebo+PCV Group"]},{"type":"BIOLOGICAL","name":"Hiberix","description":"Hiberix (Hib) was administered intramuscularly on Day 1, Day 61, and Day 121.","armGroupLabels":["MenB+PCV Group","Placebo+PCV Group"]},{"type":"BIOLOGICAL","name":"Rotarix","description":"Rotarix (HRV) was administered intramuscularly on Day 1 and Day 61.","armGroupLabels":["MenB+PCV Group","Placebo+PCV Group"]},{"type":"BIOLOGICAL","name":"M-M-R II","description":"M-M-R II (MMR) was administered intramuscularly on Day 301.","armGroupLabels":["MenB+PCV Group","Placebo+PCV Group"]},{"type":"BIOLOGICAL","name":"Varivax","description":"Varivax (VV) was administered intramuscularly on Day 301.","armGroupLabels":["MenB+PCV Group","Placebo+PCV Group"]},{"type":"BIOLOGICAL","name":"Placebo (saline water)","description":"Placebo was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.","armGroupLabels":["Placebo+PCV Group"]},{"type":"BIOLOGICAL","name":"Prevnar 20","description":"Prevnar 20 (PCV13) was administered intramuscularly as a booster dose on Day 301 group who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose.","armGroupLabels":["MenB+PCV Group","Placebo+PCV Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants Reporting Any Solicited Administration Site Events After the First Vaccination Administered at Day 1","description":"Assessed solicited administration site events include injection site tenderness (administration site pain), erythema (redness), swelling and induration. Any solicited administration site events = occurrence of the event regardless of intensity grade. Rotarix was administered orally; therefore, no administration site events were analyzed.","timeFrame":"Day 1 to Day 7"},{"measure":"Number of Participants Reporting Any Solicited Systemic Events After the First Vaccination Administered at Day 1","description":"Assessed systemic events include change in eating habits, sleepiness, vomiting, diarrhea, irritability, persistent crying, and fever, defined as body temperature greater than or equal to (≥)38.0°C/100.4°F. Any solicited systemic events = occurrence of the event regardless of intensity grade.","timeFrame":"Day 1 to Day 7"},{"measure":"Number of Participants Reporting Any Solicited Administration Site Events After the Second Vaccination Administered at Day 61","description":"Rotarix was administered orally; therefore, no administration site events were analyzed.","timeFrame":"Day 61 to Day 67"},{"measure":"Number of Participants Reporting Any Solicited Systemic Events After the Second Vaccination Administered at Day 61","timeFrame":"Day 61 to Day 67"},{"measure":"Number of Participants Reporting Any Solicited Administration Site Events After the Third Vaccination Administered at Day 121","timeFrame":"Day 121 to Day 127"},{"measure":"Number of Participants Reporting Any Solicited Systemic Events After the Third Vaccination Administered at Day 121","timeFrame":"Day 121 to Day 127"},{"measure":"Number of Participants Reporting Any Solicited Administration Site Events After the Fourth Vaccination Administered at Day 301","timeFrame":"Day 301 to Day 307"},{"measure":"Number of Participants Reporting Any Solicited Systemic Events After the Fourth Vaccination Administered at Day 301","timeFrame":"Day 301 to Day 307"},{"measure":"Number of Participants With Any Solicited Systemic AEs During the 30 Days After the Fourth Vaccination at Day 301","description":"Systemic events assessed included rash, parotid/salivary gland swelling, and fever. These systemic adverse events were recorded for 30 days following MMR and VV vaccine administration. Any solicited systemic events = occurrence of the event regardless of intensity grade.","timeFrame":"Day 301 to Day 330"},{"measure":"Number of Participants Reporting Any Unsolicited Adverse Events (AEs) After the First Vaccination Administered at Day 1","description":"An unsolicited AEs is an AE that is not solicited using a subject diary and that is spontaneously communicated by the parent(s)/LAR(s) who has signed the informed consent or a solicited local or systemic AE that continues beyond the solicited period after vaccination. Any = occurrence of the event regardless of the intensity grade.","timeFrame":"Day 1 to Day 30"},{"measure":"Number of Participants Reporting Any Unsolicited AEs After the Second Vaccination Administered at Day 61","timeFrame":"Day 61 to Day 90"},{"measure":"Number of Participants Reporting Any Unsolicted AEs After the Third Vaccination Administered at Day 121","timeFrame":"Day 121 to Day 150"},{"measure":"Number of Participants Reporting Any Unsolicited AEs After the Fourth Vaccination Administered at Day 301","timeFrame":"Day 301 to Day 330"},{"measure":"Number of Participants Reporting Any SAEs, AEs Leading to Withdrawal, AESIs and MAAEs","description":"An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization and that results in disability/incapacity. An AE leading to withdrawal includes any AEs/SAEs collected and recorded from the time of the 1st receipt of study vaccines until study end which are identified as reasons for withdrawal of the participant from the study. AESIs are pre-defined (serious or non-serious) AEs of scientific and medical concern specific to the product or program which might warrant further investigation in order to characterize and understand it. MAAEs includes any AEs that required hospitalization, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits.","timeFrame":"Day 1 up to study end (Day 481 for participants who have not reached 6-month follow-up at the time of Protocol Amendment 7; Day 661 for all others)"},{"measure":"Percentage of Participants With Human Serum Bactericidal Assay (hSBA) Antibody Titers >= Lower Limit of Quantitation (LLOQ) for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4) and M13520 (NHBA)","description":"Serum bactericidal activity is assessed using human complement (hSBA) against Neisseria meningitidis serogroup B test strains: M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA). The sufficiency of the immune response to rMenB+OMV NZ at one month after the third vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ LLOQ is ≥ 60% for each of the M14459, 96217, NZ98/254, M13520 test strain. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.","timeFrame":"At Day 151 (1 month after the third vaccination)"},{"measure":"Percentage of Participants With hSBA Titers >= LLOQ Against All Serogroup B Test Strains Combined (Composite Response)","description":"The immune response to the rMenB+OMV NZ vaccine is assessed by measuring serum bactericidal activity using hSBA against four Neisseria meningitidis serogroup B test strains: M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA). The composite response is defined as the percentage of participants with hSBA titers ≥ Lower Limit of Quantitation (LLOQ) across all four strains combined. The sufficiency of the immune response to rMenB+OMV NZ at one month after the third vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ LLOQ is ≥ 50% for all strains combined. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.","timeFrame":"At Day 151 (1 month after the third vaccination)"},{"measure":"Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA) and >= 16 for Strain 96217","description":"Serum bactericidal activity is assessed using human complement (hSBA) against Neisseria meningitidis serogroup B test strains: M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA). The sufficiency of the immune response to rMenB+OMV NZ at one month after the 4th vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ 8 (for strains M14459, NZ98/254, M13520) and ≥16 (for strain 96217) is ≥75% for each of the M14459, 96217, NZ98/254, M13520 test strains. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.","timeFrame":"At Day 331 (1 month after the fourth vaccination)"},{"measure":"Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp), NZ98/254 (PorA P1.4), and M13520 (NHBA) and >= 16 for Strain 96217 (NadA) (Composite Response Across All Strains)","description":"The immune response to the rMenB+OMV NZ vaccine is assessed by measuring serum bactericidal activity using hSBA against four Neisseria meningitidis serogroup B test strains: M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA). The composite response is defined as the percentage of participants with hSBA titers ≥ Lower Limit of Quantitation (LLOQ) across all four strains combined. The sufficiency of the immune response to rMenB+OMV NZ at one month after the 4th vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ 8 (for strains M14459, NZ98/254, M13520) and ≥16 (for strain 96217) is ≥65% for all strains combined. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.","timeFrame":"At Day 331 (1 month after the fourth vaccination)"},{"measure":"Adjusted Geometric Mean Concentrations (GMCs) of Immunoglobubin (IgG) Antibodies Against 13 PCV13 Antigens at 1 Month After Third Vaccination","description":"The immune response to PCV13 is evaluated by measuring IgG levels using electrochemiluminescence (ECL) assay. Adjusted GMCs are assessed for each of the 13 PCV13 antigens at 1 month after the third vaccination.","timeFrame":"At Day 151 (1 month after the third vaccination)"}],"secondaryOutcomes":[{"measure":"Adjusted GMCs of IgG Antibodies Against 13 PCV13 Antigens at 1 Month After the Fourth Vaccination Administered at Day 301","description":"The immune response to PCV13 is evaluated by measuring IgG levels using ECL assay. Adjusted GMCs are assessed for each of the 13 PCV13 antigens at 1 month after the 4th vaccination.","timeFrame":"At Day 331 (1 month after the fourth vaccination)"},{"measure":"Percentage of Participants With Serum Pneumococcal Anti-capsular Polysaccharide IgG >= 0.35 μg/mL","description":"The immune response to PCV13 is evaluated by measuring the percentage of participants with serum IgG concentrations ≥ 0.35 μg/mL for each of the 13 PCV13 antigens at 1 month after the third and fourth vaccinations.","timeFrame":"At Day 151 (1 month after the third vaccination) and Day 331 (1 month after the fourth vaccination)"},{"measure":"Adjusted GMCs Against 3 Pertussis Antigens (Pertussis Toxin [PT], Pertactin [PRN], Filamentous Hemagglutinin [FHA])","description":"The immune response to DTaP-HBV-IPV (Pediarix) vaccine is evaluated. IgG concentrations for pertussis antigens (PT, FHA, PRN) are measured at 1 month after the third vaccination and are expressed as international units per millilitre (IU/mL).","timeFrame":"At Day 151 (1 month after the third vaccination)"},{"measure":"Percentage of Participants With Antibodies Concentrations Against Hepatitis B Surface Antigen (AntiHBsAg) >= 10 mIU/mL","description":"The immune response to DTaP-HBV-IPV vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for Hepatitis B (HepB) antigens are measured at 1 month after the third vaccination.","timeFrame":"At Day 151 (1 month after the third vaccination)"},{"measure":"Percentage of Participants With Anti-diphtheria and Anti-tetanus Antibody Concentrations >= 0.1 IU/mL","description":"The immune response to DTaP-HBV-IPV vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for diphtheria (D) and tetanus (T) were measured at 1 month after the third vaccination.","timeFrame":"At Day 151 (1 month after the third vaccination)"},{"measure":"Percentage of Participants With Anti-polyribosyl-ribitol Phosphate (PRP) Concentration >= 0.15 µg/mL and >= 1 µg/mL","description":"The immune response to Hib vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for Haemophilus influenzae type b (Hib) are measured at 1 month after the third vaccination.","timeFrame":"At Day 151 (1 month after the third vaccination)"},{"measure":"Adjusted GMCs for Anti-measles Antibodies","description":"The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for measles antigens are measured using adjusted GMCs at 1 month after fourth vaccination and are expressed as milli-International Units per milliliter (mIU/mL).","timeFrame":"At Day 331 (1 month after the fourth vaccination)"},{"measure":"Adjusted GMCs for Anti-mumps Antibodies","description":"The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for mumps antigens are measured using adjusted GMCs at 1 month after fourth vaccination.","timeFrame":"At Day 331 (1 month after the fourth vaccination)"},{"measure":"Adjusted GMCs for Anti-rubella Antibodies","description":"The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for rubella antigens are measured using adjusted GMCs at 1 month after fourth vaccination.","timeFrame":"At Day 331 (1 month after the fourth vaccination)"},{"measure":"Adjusted GMCs for Anti-Varicella (VV) Antibodies","description":"The immune response to varicella (VV) vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for varicella antigens are measured using GMCs at 1 month after fourth vaccination.","timeFrame":"At Day 331 (1 month after the fourth vaccination)"},{"measure":"Percentage of Participants With hSBA Antibody Titers >= 5, >= 8 and >=16 for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)","description":"This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.","timeFrame":"At Day 151 (1 month after the third vaccination)"},{"measure":"Percentage of Participants With hSBA Antibody Titers >= 5 and >= 8 for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)","description":"This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.","timeFrame":"At Day 301 (6 months after third vaccination)"},{"measure":"Percentage of Participants With hSBA Antibody Titers >= 5 for Each of the Serogroup B Test Strain M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)","description":"This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.","timeFrame":"At Day 331 (1 month after the fourth vaccination)"},{"measure":"hSBA Geometric Mean Titers (GMTs) Against Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)","description":"This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.","timeFrame":"At Day 151 (1 month after the third vaccination), Day 301 (6 months after the third vaccination), and Day 331 (1 month after the fourth vaccination)"},{"measure":"hSBA Geometric Mean Ratios (GMRs) Over Pre Fourth Vaccination Against Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)","description":"This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.","timeFrame":"At Day 331 (1 month after the fourth vaccination) compared to Day 301 (pre-fourth vaccination)"},{"measure":"Percentage of Participants With hSBA Antibody Titers >= LLOQ for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)","description":"This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.","timeFrame":"At Day 301 (6 months after the third vaccination) and Day 331 (1 month after the fourth vaccination)"},{"measure":"Percentage of Participants With 4-fold Rise in hSBA Titers for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)","description":"A 4-fold rise in hSBA titers is defined as - if pre-vaccination titer \\<Limit of Detection (LOD), then a post-vaccination titer \\>= 4 times the LOD or \\>= LLOQ, whichever is greater; - if pre-vaccination titer is \\>= LOD but \\<LLOQ, then a post-vaccination titer \\>= 4 times the LLOQ; - if pre-vaccination titer is \\>= LLOQ, then a post-vaccination titer \\>= 4 times the pre-vaccination titer, where pre-vaccination titer=pre-4th dose titers (Day 301). This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.","timeFrame":"At Day 331 (1 month after the fourth vaccination) relative to Day 301 (pre-fourth vaccination)"},{"measure":"Percentage of Participants With Anti-HBs Antibody Concentrations >= 100 mIU/mL","timeFrame":"At Day 151 (1 month after the third vaccination)"},{"measure":"GMCs for Anti-HBsAg Antibodies","timeFrame":"At Day 151 (1 month after the third vaccination)"},{"measure":"Percentage of Participants With Anti-diphtheria and Anti-tetanus Antibody Concentrations >= 1 IU/mL","timeFrame":"At Day 151 (1 month after the third vaccination)"},{"measure":"GMCs for Anti-diphtheria and Anti-tetanus Antibodies","timeFrame":"At Day 151 (1 month after the third vaccination)"},{"measure":"Percentage of Participants With Anti-polio Type 1, 2 and 3 Neutralization Antibody Titers >= 8","timeFrame":"At Day 151 (1 month after the third vaccination)"},{"measure":"Percentage of Participants With Seroresponse for Anti-Varicella (VV), Anti-measles Virus, Anti-mumps Virus and Anti-rubella Virus Antibodies","description":"Seroresponse is defined as post-vaccination anti-VZV virus, anti-measles virus, anti-mumps virus and anti-rubella virus antibody concentration \\>= a protective threshold among participants who were seronegative (antibody concentration \\< assay cut-off) before vaccination.","timeFrame":"At Day 331 (1 month after the fourth vaccination)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nAll subjects must satisfy all the following criteria at study entry:\n\n* Subjects' parent(s)/Legally Acceptable Representative(s) \\[LAR(s)\\] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol (e.g. completion of the eDiary, return for follow-up visits).\n* Written informed consent obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure.\n* A male or female between, and including, 42 and 84 days of age (i.e., 6 through 12 weeks) at the time of the 1st vaccination.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n* Born full-term (i.e. after a gestation period of ≥ 38 weeks).\n\nExclusion Criteria:\n\nIf any exclusion criterion applies, the subject must not be included in the study:\n\n• Child in care\n\nEach subject must not have:\n\n* Progressive, unstable or uncontrolled clinical conditions.\n* Hypersensitivity, including allergy to any component of vaccines, medicinal product or medical equipment whose use is foreseen in this study.\n* Hypersensitivity to latex.\n* Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.\n* Abnormal function of the immune system resulting from:\n\n  * Clinical conditions.\n  * Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days from birth.\n  * Administration of antineoplastic and immunomodulating agents or radiotherapy for any duration from birth.\n  * Autoimmune disorders (including, but not limited to: blood, endocrine, hepatic, muscular, nervous system or skin autoimmune disorders; lupus erythematosus and associated conditions; rheumatoid arthritis and associated conditions; scleroderma and associated disorders) or immunodeficiency syndromes (including, but not limited to: acquired immunodeficiency syndromes and primary immunodeficiency syndromes).\n* Received immunoglobulins or any blood products from birth.\n* Received an investigational or non-registered medicinal product from birth.\n* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study.\n* Neuroinflammatory disorders (including but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), congenital and peripartum neurological conditions, encephalopathies, seizures (including all subtypes such as: absence seizures, generalised tonic-clonic seizures, partial complex seizures, partial simple seizures or febrile convulsions).\n* Congenital or peripartum disorders resulting in a chronic condition (including but not limited to: chromosomal abnormalities, cerebral palsy, metabolism or synthesis disorders, cardiac disorders).\n* Study personnel as an immediate family or household member.\n* Current or previous, confirmed or suspected disease caused by N. meningitidis\n* Household contact with and/or intimate exposure from birth to an individual with laboratory confirmed N. meningitidis and/or Streptococcus pneumoniae infection or colonization.\n* Previous administration of meningococcal B or pneumococcal vaccine at any time prior to informed consent.\n* Received a dose of DTPa-HBV-IPV, HRV, MMR, VV and/or Hib at any time prior to informed consent. Receipt of one dose of HBV up to 4 weeks prior to informed con-sent is allowed.\n* Serious chronic illness.\n* Uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for Intussusception (IS).","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"GSK Clinical Trials","affiliation":"GlaxoSmithKline","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GSK Investigational Site","city":"Birmingham","state":"Alabama","zip":"35205","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"GSK Investigational Site","city":"Fayetteville","state":"Arkansas","zip":"72703","country":"United States","geoPoint":{"lat":36.06258,"lon":-94.15743}},{"facility":"GSK Investigational Site","city":"Jonesboro","state":"Arkansas","zip":"72401","country":"United States","geoPoint":{"lat":35.8423,"lon":-90.70428}},{"facility":"GSK Investigational Site","city":"Anaheim","state":"California","zip":"92804","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"GSK Investigational Site","city":"Oakland","state":"California","zip":"94611","country":"United States","geoPoint":{"lat":37.80437,"lon":-122.2708}},{"facility":"GSK Investigational Site","city":"Roseville","state":"California","zip":"95661","country":"United States","geoPoint":{"lat":38.75212,"lon":-121.28801}},{"facility":"GSK Investigational Site","city":"Walnut Creek","state":"California","zip":"94596","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"GSK Investigational Site","city":"West Covina","state":"California","zip":"91790","country":"United States","geoPoint":{"lat":34.06862,"lon":-117.93895}},{"facility":"GSK Investigational Site","city":"Lake Mary","state":"Florida","zip":"32746","country":"United States","geoPoint":{"lat":28.75888,"lon":-81.31784}},{"facility":"GSK Investigational Site","city":"Miami","state":"Florida","zip":"33142","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"GSK Investigational Site","city":"Tampa","state":"Florida","zip":"33613","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"GSK Investigational Site","city":"Nampa","state":"Idaho","zip":"83686","country":"United States","geoPoint":{"lat":43.54072,"lon":-116.56346}},{"facility":"GSK Investigational Site","city":"Nampa","state":"Idaho","zip":"83702","country":"United States","geoPoint":{"lat":43.54072,"lon":-116.56346}},{"facility":"GSK Investigational Site","city":"Newton","state":"Kansas","zip":"67114","country":"United States","geoPoint":{"lat":38.04668,"lon":-97.34504}},{"facility":"GSK Investigational Site","city":"Topeka","state":"Kansas","zip":"66604","country":"United States","geoPoint":{"lat":39.04833,"lon":-95.67804}},{"facility":"GSK Investigational Site","city":"Bardstown","state":"Kentucky","zip":"40004","country":"United States","geoPoint":{"lat":37.80923,"lon":-85.4669}},{"facility":"GSK Investigational Site","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"GSK Investigational Site","city":"Louisville","state":"Kentucky","zip":"40207","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"GSK Investigational Site","city":"Louisville","state":"Kentucky","zip":"40291","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"GSK Investigational Site","city":"Baltimore","state":"Maryland","zip":"21021","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"GSK Investigational Site","city":"Fall River","state":"Massachusetts","zip":"02721","country":"United States","geoPoint":{"lat":41.70149,"lon":-71.15505}},{"facility":"GSK Investigational Site","city":"Bingham Farms","state":"Michigan","zip":"48025","country":"United States","geoPoint":{"lat":42.51587,"lon":-83.27326}},{"facility":"GSK Investigational Site","city":"Kansas City","state":"Missouri","zip":"64108","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"GSK Investigational Site","city":"Lincoln","state":"Nebraska","zip":"68516","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"GSK Investigational Site","city":"Omaha","state":"Nebraska","zip":"68128","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"GSK Investigational Site","city":"Liverpool","state":"New York","zip":"13090","country":"United States","geoPoint":{"lat":43.10646,"lon":-76.2177}},{"facility":"GSK Investigational Site","city":"Syracuse","state":"New York","zip":"13210","country":"United States","geoPoint":{"lat":43.04812,"lon":-76.14742}},{"facility":"GSK Investigational Site","city":"Boone","state":"North Carolina","zip":"28607","country":"United States","geoPoint":{"lat":36.21679,"lon":-81.67455}},{"facility":"GSK Investigational Site","city":"Raleigh","state":"North Carolina","zip":"27609","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"facility":"GSK Investigational Site","city":"Cincinnati","state":"Ohio","zip":"45245","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"GSK Investigational Site","city":"Dayton","state":"Ohio","zip":"45406","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"GSK Investigational Site","city":"Dayton","state":"Ohio","zip":"45414","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"GSK Investigational Site","city":"Fairfield","state":"Ohio","zip":"45014","country":"United States","geoPoint":{"lat":39.34589,"lon":-84.5605}},{"facility":"GSK Investigational Site","city":"South Euclid","state":"Ohio","zip":"44121","country":"United States","geoPoint":{"lat":41.52311,"lon":-81.51846}},{"facility":"GSK Investigational Site","city":"Hermitage","state":"Pennsylvania","zip":"16148","country":"United States","geoPoint":{"lat":41.23339,"lon":-80.44868}},{"facility":"GSK Investigational Site","city":"Pittsburgh","state":"Pennsylvania","zip":"15224","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"GSK Investigational Site","city":"Charleston","state":"South Carolina","zip":"29406","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"GSK Investigational Site","city":"Sioux Falls","state":"South Dakota","zip":"57105","country":"United States","geoPoint":{"lat":43.54369,"lon":-96.72796}},{"facility":"GSK Investigational Site","city":"Clarksville","state":"Tennessee","zip":"37040","country":"United States","geoPoint":{"lat":36.52977,"lon":-87.35945}},{"facility":"GSK Investigational Site","city":"Kingsport","state":"Tennessee","zip":"37660","country":"United States","geoPoint":{"lat":36.54843,"lon":-82.56182}},{"facility":"GSK Investigational Site","city":"Beaumont","state":"Texas","zip":"77706","country":"United States","geoPoint":{"lat":30.08605,"lon":-94.10185}},{"facility":"GSK Investigational Site","city":"Bryan","state":"Texas","zip":"77802","country":"United States","geoPoint":{"lat":30.67436,"lon":-96.36996}},{"facility":"GSK Investigational Site","city":"Edinburg","state":"Texas","zip":"78504","country":"United States","geoPoint":{"lat":26.30174,"lon":-98.16334}},{"facility":"GSK Investigational Site","city":"Houston","state":"Texas","zip":"77065","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"GSK Investigational Site","city":"Houston","state":"Texas","zip":"77090","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"GSK Investigational Site","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"GSK Investigational Site","city":"San Antonio","state":"Texas","zip":"78244","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"GSK Investigational Site","city":"Layton","state":"Utah","zip":"84041","country":"United States","geoPoint":{"lat":41.06022,"lon":-111.97105}},{"facility":"GSK Investigational Site","city":"Orem","state":"Utah","zip":"84057","country":"United States","geoPoint":{"lat":40.2969,"lon":-111.69465}},{"facility":"GSK Investigational Site","city":"Provo","state":"Utah","zip":"84604","country":"United States","geoPoint":{"lat":40.23384,"lon":-111.65853}},{"facility":"GSK Investigational Site","city":"Roy","state":"Utah","zip":"84067","country":"United States","geoPoint":{"lat":41.16161,"lon":-112.02633}},{"facility":"GSK Investigational Site","city":"Salt Lake City","state":"Utah","zip":"84121","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"GSK Investigational Site","city":"Syracuse","state":"Utah","zip":"84075","country":"United States","geoPoint":{"lat":41.08939,"lon":-112.06467}},{"facility":"GSK Investigational Site","city":"Richmond","state":"Virginia","zip":"23298","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"GSK Investigational Site","city":"Spokane","state":"Washington","zip":"99202","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"GSK Investigational Site","city":"Marshfield","state":"Wisconsin","zip":"54449","country":"United States","geoPoint":{"lat":44.66885,"lon":-90.1718}},{"facility":"GSK Investigational Site","city":"San Juan","zip":"00907","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"IPD for this study will be made available via the Clinical Study Data Request site.","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR"],"timeFrame":"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","accessCriteria":"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.","url":"https://clinicalstudydatarequest.com"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Out of the 1196 participants enrolled, only 1184 participants were included in the Exposed Set and started the study.","groups":[{"id":"FG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"FG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"781"},{"groupId":"FG001","numSubjects":"403"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"642"},{"groupId":"FG001","numSubjects":"326"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"139"},{"groupId":"FG001","numSubjects":"77"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"25"}]},{"type":"Consent withdrawal not due to AEs","reasons":[{"groupId":"FG000","numSubjects":"54"},{"groupId":"FG001","numSubjects":"18"}]},{"type":"Migrated / Moved from the study area","reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"Not willing / Not able to be contacted","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"13"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Protocol Deviation","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"BG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"781"},{"groupId":"BG001","value":"403"},{"groupId":"BG002","value":"1184"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Weeks","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.6","spread":"1.0"},{"groupId":"BG001","value":"8.8","spread":"1.0"},{"groupId":"BG002","value":"8.7","spread":"1.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"380"},{"groupId":"BG001","value":"196"},{"groupId":"BG002","value":"576"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"401"},{"groupId":"BG001","value":"207"},{"groupId":"BG002","value":"608"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"21"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"60"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"117"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"531"},{"groupId":"BG001","value":"288"},{"groupId":"BG002","value":"819"}]}]},{"title":"Other (Not specified)","categories":[{"measurements":[{"groupId":"BG000","value":"107"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"163"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Reporting Any Solicited Administration Site Events After the First Vaccination Administered at Day 1","description":"Assessed solicited administration site events include injection site tenderness (administration site pain), erythema (redness), swelling and induration. Any solicited administration site events = occurrence of the event regardless of intensity grade. Rotarix was administered orally; therefore, no administration site events were analyzed.","populationDescription":"Analysis was performed on the Solicited Safety Set, which included all participants who received a study vaccination and had solicited adverse event data available for the specified duration.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 to Day 7","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"768"},{"groupId":"OG001","value":"394"}]}],"classes":[{"title":"Erythema, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"768"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"156"}]}]},{"title":"Erythema, Prevnar 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"768"},{"groupId":"OG001","value":"393"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"39"}]}]},{"title":"Erythema, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"394"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"25"}]}]},{"title":"Erythema, Pediarix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"768"},{"groupId":"OG001","value":"391"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"32"}]}]},{"title":"Erythema, Hiberix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"767"},{"groupId":"OG001","value":"393"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"17"}]}]},{"title":"Induration, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"768"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"204"}]}]},{"title":"Induration, Prevnar 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"768"},{"groupId":"OG001","value":"393"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"67"}]}]},{"title":"Induration, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"394"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"22"}]}]},{"title":"Induration, Pediarix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"768"},{"groupId":"OG001","value":"391"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"34"}]}]},{"title":"Induration, Hiberix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"767"},{"groupId":"OG001","value":"393"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"20"}]}]},{"title":"Swelling, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"768"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"132"}]}]},{"title":"Swelling, Prevnar 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"768"},{"groupId":"OG001","value":"393"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"34"}]}]},{"title":"Swelling, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"394"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"21"}]}]},{"title":"Swelling, Pediarix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"768"},{"groupId":"OG001","value":"391"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"21"}]}]},{"title":"Swelling, Hiberix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"767"},{"groupId":"OG001","value":"393"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"12"}]}]},{"title":"Tenderness, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"768"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"352"}]}]},{"title":"Tenderness, Prevnar 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"768"},{"groupId":"OG001","value":"393"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"310"},{"groupId":"OG001","value":"107"}]}]},{"title":"Tenderness, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"394"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"81"}]}]},{"title":"Tenderness, Pediarix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"768"},{"groupId":"OG001","value":"391"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"92"}]}]},{"title":"Tenderness, Hiberix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"767"},{"groupId":"OG001","value":"393"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"74"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Any Solicited Systemic Events After the First Vaccination Administered at Day 1","description":"Assessed systemic events include change in eating habits, sleepiness, vomiting, diarrhea, irritability, persistent crying, and fever, defined as body temperature greater than or equal to (≥)38.0°C/100.4°F. Any solicited systemic events = occurrence of the event regardless of intensity grade.","populationDescription":"Analysis was performed on the Solicited Safety Set. Only participants with solicited adverse event data available for the specified duration were included in this analysis.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 to Day 7","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"768"},{"groupId":"OG001","value":"394"}]}],"classes":[{"title":"Change in eating habits","categories":[{"measurements":[{"groupId":"OG000","value":"329"},{"groupId":"OG001","value":"122"}]}]},{"title":"Diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"84"}]}]},{"title":"Irritability","categories":[{"measurements":[{"groupId":"OG000","value":"601"},{"groupId":"OG001","value":"242"}]}]},{"title":"Persistent crying","categories":[{"measurements":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"89"}]}]},{"title":"Sleepiness","categories":[{"measurements":[{"groupId":"OG000","value":"560"},{"groupId":"OG001","value":"246"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"79"}]}]},{"title":"Fever","categories":[{"measurements":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"34"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Any Solicited Administration Site Events After the Second Vaccination Administered at Day 61","description":"Rotarix was administered orally; therefore, no administration site events were analyzed.","populationDescription":"Analysis was performed on the Solicited Safety Set. Only participants with solicited adverse event data available for the specified duration were included in this analysis.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 61 to Day 67","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"699"},{"groupId":"OG001","value":"364"}]}],"classes":[{"title":"Erythema, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"699"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"200"}]}]},{"title":"Erythema, Prevnar 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"697"},{"groupId":"OG001","value":"363"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"62"}]}]},{"title":"Erythema, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"364"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"44"}]}]},{"title":"Erythema, Pediarix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"695"},{"groupId":"OG001","value":"360"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"54"}]}]},{"title":"Erythema, Hiberix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"697"},{"groupId":"OG001","value":"363"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"41"}]}]},{"title":"Induration, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"699"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"213"}]}]},{"title":"Induration, Prevnar 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"697"},{"groupId":"OG001","value":"363"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"63"}]}]},{"title":"Induration, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"364"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"32"}]}]},{"title":"Induration, Pediarix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"695"},{"groupId":"OG001","value":"360"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"55"}]}]},{"title":"Induration, Hiberix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"697"},{"groupId":"OG001","value":"363"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"32"}]}]},{"title":"Swelling, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"699"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"112"}]}]},{"title":"Swelling, Prevnar 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"697"},{"groupId":"OG001","value":"363"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"38"}]}]},{"title":"Swelling, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"364"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"19"}]}]},{"title":"Swelling, Pediarix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"695"},{"groupId":"OG001","value":"360"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"33"}]}]},{"title":"Tenderness, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"699"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"269"}]}]},{"title":"Swelling, Hiberix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"697"},{"groupId":"OG001","value":"363"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"17"}]}]},{"title":"Tenderness, Prevnar 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"697"},{"groupId":"OG001","value":"363"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"81"}]}]},{"title":"Tenderness, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"364"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"65"}]}]},{"title":"Tenderness, Pediarix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"695"},{"groupId":"OG001","value":"360"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"67"}]}]},{"title":"Tenderness, Hiberix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"697"},{"groupId":"OG001","value":"363"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"52"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Any Solicited Systemic Events After the Second Vaccination Administered at Day 61","populationDescription":"Analysis was performed on the Solicited Safety Set. Only participants with solicited adverse event data available for the specified duration were included in this analysis.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 61 to Day 67","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"699"},{"groupId":"OG001","value":"364"}]}],"classes":[{"title":"Change in eating habits","categories":[{"measurements":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"90"}]}]},{"title":"Diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"66"}]}]},{"title":"Irritability","categories":[{"measurements":[{"groupId":"OG000","value":"514"},{"groupId":"OG001","value":"215"}]}]},{"title":"Persistent crying","categories":[{"measurements":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"73"}]}]},{"title":"Sleepiness","categories":[{"measurements":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"183"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"49"}]}]},{"title":"Fever","categories":[{"measurements":[{"groupId":"OG000","value":"269"},{"groupId":"OG001","value":"64"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Any Solicited Administration Site Events After the Third Vaccination Administered at Day 121","populationDescription":"Analysis was performed on the Solicited Safety Set. Only participants with solicited adverse event data available for the specified duration were included in this analysis.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 121 to Day 127","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"676"},{"groupId":"OG001","value":"352"}]}],"classes":[{"title":"Erythema, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"676"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"181"}]}]},{"title":"Erythema, Prevnar 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"674"},{"groupId":"OG001","value":"352"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"71"}]}]},{"title":"Erythema, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"351"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"43"}]}]},{"title":"Erythema, Pediarix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"672"},{"groupId":"OG001","value":"351"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"65"}]}]},{"title":"Erythema, Hiberix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"673"},{"groupId":"OG001","value":"351"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"38"}]}]},{"title":"Induration, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"676"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"187"}]}]},{"title":"Induration, Prevnar 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"674"},{"groupId":"OG001","value":"352"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"60"}]}]},{"title":"Induration, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"351"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"26"}]}]},{"title":"Induration, Pediarix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"672"},{"groupId":"OG001","value":"351"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"70"}]}]},{"title":"Induration, Hiberix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"673"},{"groupId":"OG001","value":"351"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"28"}]}]},{"title":"Swelling, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"676"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"103"}]}]},{"title":"Swelling, Prevnar 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"674"},{"groupId":"OG001","value":"352"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"39"}]}]},{"title":"Swelling, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"351"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"13"}]}]},{"title":"Swelling, Pediarix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"672"},{"groupId":"OG001","value":"351"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"28"}]}]},{"title":"Swelling, Hiberix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"673"},{"groupId":"OG001","value":"351"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"8"}]}]},{"title":"Tenderness, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"676"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"244"}]}]},{"title":"Tenderness, Prevnar 13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"674"},{"groupId":"OG001","value":"352"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"66"}]}]},{"title":"Tenderness, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"351"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"52"}]}]},{"title":"Tenderness, Pediarix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"672"},{"groupId":"OG001","value":"351"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"58"}]}]},{"title":"Tenderness, Hiberix","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"673"},{"groupId":"OG001","value":"351"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"45"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Any Solicited Systemic Events After the Third Vaccination Administered at Day 121","populationDescription":"Analysis was performed on the Solicited Safety Set. Only participants with solicited adverse event data available for the specified duration were included in this analysis.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 121 to Day 127","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"676"},{"groupId":"OG001","value":"352"}]}],"classes":[{"title":"Change in eating habits","categories":[{"measurements":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"94"}]}]},{"title":"Diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"44"}]}]},{"title":"Irritability","categories":[{"measurements":[{"groupId":"OG000","value":"454"},{"groupId":"OG001","value":"179"}]}]},{"title":"Persistent crying","categories":[{"measurements":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"59"}]}]},{"title":"Sleepiness","categories":[{"measurements":[{"groupId":"OG000","value":"326"},{"groupId":"OG001","value":"142"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"46"}]}]},{"title":"Fever","categories":[{"measurements":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"55"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Any Solicited Administration Site Events After the Fourth Vaccination Administered at Day 301","populationDescription":"Analysis was performed on the Solicited Safety Set. Only participants with solicited adverse event data available for the specified duration were included in this analysis.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 301 to Day 307","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"579"},{"groupId":"OG001","value":"299"}]}],"classes":[{"title":"Erythema, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"578"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"180"}]}]},{"title":"Erythema, Prevnar 13/20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"564"},{"groupId":"OG001","value":"288"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"37"}]}]},{"title":"Erythema, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"298"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"25"}]}]},{"title":"Erythema, MMR II","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"569"},{"groupId":"OG001","value":"294"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"24"}]}]},{"title":"Erythema, Varivax","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"565"},{"groupId":"OG001","value":"293"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"20"}]}]},{"title":"Induration, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"579"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"179"}]}]},{"title":"Induration, Prevnar 13/20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"564"},{"groupId":"OG001","value":"288"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"32"}]}]},{"title":"Induration, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"298"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"24"}]}]},{"title":"Induration, MMR II","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"569"},{"groupId":"OG001","value":"294"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"17"}]}]},{"title":"Induration, Varivax","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"565"},{"groupId":"OG001","value":"293"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"15"}]}]},{"title":"Swelling, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"578"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91"}]}]},{"title":"Swelling, Prevnar 13/20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"564"},{"groupId":"OG001","value":"287"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"18"}]}]},{"title":"Swelling, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"299"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"8"}]}]},{"title":"Swelling, MMR II","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"569"},{"groupId":"OG001","value":"294"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"12"}]}]},{"title":"Swelling, Varivax","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"565"},{"groupId":"OG001","value":"293"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"9"}]}]},{"title":"Tenderness, Bexsero","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"579"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"223"}]}]},{"title":"Tenderness, Prevnar 13/20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"564"},{"groupId":"OG001","value":"287"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"35"}]}]},{"title":"Tenderness, Placebo","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"298"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"31"}]}]},{"title":"Tenderness, MMR II","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"569"},{"groupId":"OG001","value":"294"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"28"}]}]},{"title":"Tenderness, Varivax","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"565"},{"groupId":"OG001","value":"293"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"27"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Any Solicited Systemic Events After the Fourth Vaccination Administered at Day 301","populationDescription":"Analysis was performed on the Solicited Safety Set. Only participants with solicited adverse event data available for the specified duration were included in this analysis.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 301 to Day 307","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"614"},{"groupId":"OG001","value":"314"}]}],"classes":[{"title":"Change in eating habits","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"608"},{"groupId":"OG001","value":"312"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"75"}]}]},{"title":"Diarrhea","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"609"},{"groupId":"OG001","value":"313"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"40"}]}]},{"title":"Irritability","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"614"},{"groupId":"OG001","value":"313"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"401"},{"groupId":"OG001","value":"153"}]}]},{"title":"Persistent crying","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"609"},{"groupId":"OG001","value":"312"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"29"}]}]},{"title":"Rash","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"607"},{"groupId":"OG001","value":"312"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"30"}]}]},{"title":"Sleepiness","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"609"},{"groupId":"OG001","value":"314"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"273"},{"groupId":"OG001","value":"96"}]}]},{"title":"Vomiting","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"609"},{"groupId":"OG001","value":"312"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"32"}]}]},{"title":"Fever","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"608"},{"groupId":"OG001","value":"312"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"22"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Any Solicited Systemic AEs During the 30 Days After the Fourth Vaccination at Day 301","description":"Systemic events assessed included rash, parotid/salivary gland swelling, and fever. These systemic adverse events were recorded for 30 days following MMR and VV vaccine administration. Any solicited systemic events = occurrence of the event regardless of intensity grade.","populationDescription":"Analysis was performed on the Solicited Safety Set. Only participants with solicited adverse event data available for the specified duration were included in this analysis.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 301 to Day 330","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"627"},{"groupId":"OG001","value":"321"}]}],"classes":[{"title":"Parotid/Salivary gland swelling","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"626"},{"groupId":"OG001","value":"321"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"17"}]}]},{"title":"Rash","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"626"},{"groupId":"OG001","value":"321"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"95"}]}]},{"title":"Fever","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"627"},{"groupId":"OG001","value":"321"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"70"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Any Unsolicited Adverse Events (AEs) After the First Vaccination Administered at Day 1","description":"An unsolicited AEs is an AE that is not solicited using a subject diary and that is spontaneously communicated by the parent(s)/LAR(s) who has signed the informed consent or a solicited local or systemic AE that continues beyond the solicited period after vaccination. Any = occurrence of the event regardless of the intensity grade.","populationDescription":"Analysis was performed on the Unsolicited Safety Set, which included all participants who received a study vaccination and had unsolicited adverse event data available for the specified duration","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 to Day 30","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"775"},{"groupId":"OG001","value":"401"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"103"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Any Unsolicited AEs After the Second Vaccination Administered at Day 61","populationDescription":"Analysis was performed on the Unsolicited Safety Set. Only participants with unsolicited adverse event data available for the specified duration were included in this analysis.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 61 to Day 90","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"745"},{"groupId":"OG001","value":"388"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"119"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Any Unsolicted AEs After the Third Vaccination Administered at Day 121","populationDescription":"Analysis was performed on the Unsolicited Safety Set. Only participants with unsolicited adverse event data available for the specified duration were included in this analysis.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 121 to Day 150","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"725"},{"groupId":"OG001","value":"374"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"120"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Any Unsolicited AEs After the Fourth Vaccination Administered at Day 301","populationDescription":"Analysis was performed on the Unsolicited Safety Set. Only participants with unsolicited adverse event data available for the specified duration were included in this analysis.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 301 to Day 330","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"668"},{"groupId":"OG001","value":"339"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"144"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Any SAEs, AEs Leading to Withdrawal, AESIs and MAAEs","description":"An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization and that results in disability/incapacity. An AE leading to withdrawal includes any AEs/SAEs collected and recorded from the time of the 1st receipt of study vaccines until study end which are identified as reasons for withdrawal of the participant from the study. AESIs are pre-defined (serious or non-serious) AEs of scientific and medical concern specific to the product or program which might warrant further investigation in order to characterize and understand it. MAAEs includes any AEs that required hospitalization, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits.","populationDescription":"Analysis was performed on the Unsolicited Safety Set. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 up to study end (Day 481 for participants who have not reached 6-month follow-up at the time of Protocol Amendment 7; Day 661 for all others)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"775"},{"groupId":"OG001","value":"401"}]}],"classes":[{"title":"AEs leading to withdrawal","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"19"}]}]},{"title":"AESIs","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}]}]},{"title":"MAAEs","categories":[{"measurements":[{"groupId":"OG000","value":"626"},{"groupId":"OG001","value":"329"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Human Serum Bactericidal Assay (hSBA) Antibody Titers >= Lower Limit of Quantitation (LLOQ) for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4) and M13520 (NHBA)","description":"Serum bactericidal activity is assessed using human complement (hSBA) against Neisseria meningitidis serogroup B test strains: M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA). The sufficiency of the immune response to rMenB+OMV NZ at one month after the third vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ LLOQ is ≥ 60% for each of the M14459, 96217, NZ98/254, M13520 test strain. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.","populationDescription":"Analysis was performed on the Per Protocol Set (PPS) for immunogenicity, which included all participants who received a study vaccination and provided immunogenicity data at one month after their third vaccination for at least 1 strain. Only participants with data available for the specified analysis at the specified timepoint were included.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"99.2% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 151 (1 month after the third vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"553"}]}],"classes":[{"title":"M14459 (fHbp)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"537"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","lowerLimit":"88.6","upperLimit":"94.9"}]}]},{"title":"96217 (NadA)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"525"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","lowerLimit":"97.9","upperLimit":"99.9"}]}]},{"title":"NZ98/254 (PorA)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"547"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.5","lowerLimit":"68.2","upperLimit":"78.3"}]}]},{"title":"M13520 (NHBA)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"553"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.0","lowerLimit":"47.3","upperLimit":"58.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With hSBA Titers >= LLOQ Against All Serogroup B Test Strains Combined (Composite Response)","description":"The immune response to the rMenB+OMV NZ vaccine is assessed by measuring serum bactericidal activity using hSBA against four Neisseria meningitidis serogroup B test strains: M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA). The composite response is defined as the percentage of participants with hSBA titers ≥ Lower Limit of Quantitation (LLOQ) across all four strains combined. The sufficiency of the immune response to rMenB+OMV NZ at one month after the third vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ LLOQ is ≥ 50% for all strains combined. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"99.2% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 151 (1 month after the third vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"524"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.7","lowerLimit":"37.0","upperLimit":"48.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA) and >= 16 for Strain 96217","description":"Serum bactericidal activity is assessed using human complement (hSBA) against Neisseria meningitidis serogroup B test strains: M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA). The sufficiency of the immune response to rMenB+OMV NZ at one month after the 4th vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ 8 (for strains M14459, NZ98/254, M13520) and ≥16 (for strain 96217) is ≥75% for each of the M14459, 96217, NZ98/254, M13520 test strains. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95.8% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 331 (1 month after the fourth vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"}]}],"classes":[{"title":"M14459 (fHbp)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.0","lowerLimit":"85.8","upperLimit":"91.7"}]}]},{"title":"96217 (NadA)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"482"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","lowerLimit":"98.5","upperLimit":"100"}]}]},{"title":"NZ98/254 (PorA P1.4)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"499"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.2","lowerLimit":"79.4","upperLimit":"86.5"}]}]},{"title":"M13520 (NHBA)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","lowerLimit":"72.5","upperLimit":"80.4"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp), NZ98/254 (PorA P1.4), and M13520 (NHBA) and >= 16 for Strain 96217 (NadA) (Composite Response Across All Strains)","description":"The immune response to the rMenB+OMV NZ vaccine is assessed by measuring serum bactericidal activity using hSBA against four Neisseria meningitidis serogroup B test strains: M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA). The composite response is defined as the percentage of participants with hSBA titers ≥ Lower Limit of Quantitation (LLOQ) across all four strains combined. The sufficiency of the immune response to rMenB+OMV NZ at one month after the 4th vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ 8 (for strains M14459, NZ98/254, M13520) and ≥16 (for strain 96217) is ≥65% for all strains combined. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95.8% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 331 (1 month after the fourth vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"478"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","lowerLimit":"58.5","upperLimit":"67.7"}]}]}]},{"type":"PRIMARY","title":"Adjusted Geometric Mean Concentrations (GMCs) of Immunoglobubin (IgG) Antibodies Against 13 PCV13 Antigens at 1 Month After Third Vaccination","description":"The immune response to PCV13 is evaluated by measuring IgG levels using electrochemiluminescence (ECL) assay. Adjusted GMCs are assessed for each of the 13 PCV13 antigens at 1 month after the third vaccination.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"98.3% Confidence Interval","unitOfMeasure":"Microgram per milliliter(µg/mL)","timeFrame":"At Day 151 (1 month after the third vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"classes":[{"title":"Serotype 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"1.4","upperLimit":"1.9"},{"groupId":"OG001","value":"1.5","lowerLimit":"1.3","upperLimit":"1.8"}]}]},{"title":"Serotype 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.4","upperLimit":"0.6"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.4","upperLimit":"0.6"}]}]},{"title":"Serotype 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.9","upperLimit":"1.3"},{"groupId":"OG001","value":"1.1","lowerLimit":"1.0","upperLimit":"1.3"}]}]},{"title":"Serotype 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"0.8","upperLimit":"1.2"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.8","upperLimit":"1.2"}]}]},{"title":"Serotype 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","lowerLimit":"2.0","upperLimit":"2.8"},{"groupId":"OG001","value":"2.5","lowerLimit":"2.1","upperLimit":"2.9"}]}]},{"title":"Serotype 6B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"1.1","upperLimit":"1.9"},{"groupId":"OG001","value":"1.8","lowerLimit":"1.4","upperLimit":"2.3"}]}]},{"title":"Serotype 7F","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","lowerLimit":"2.4","upperLimit":"3.3"},{"groupId":"OG001","value":"2.9","lowerLimit":"2.5","upperLimit":"3.3"}]}]},{"title":"Serotype 9V","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","lowerLimit":"1.1","upperLimit":"1.6"},{"groupId":"OG001","value":"1.4","lowerLimit":"1.2","upperLimit":"1.6"}]}]},{"title":"Serotype 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","lowerLimit":"4.7","upperLimit":"7.4"},{"groupId":"OG001","value":"5.8","lowerLimit":"4.8","upperLimit":"7.2"}]}]},{"title":"Serotype 18C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"1.3","upperLimit":"1.8"},{"groupId":"OG001","value":"1.5","lowerLimit":"1.3","upperLimit":"1.8"}]}]},{"title":"Serotype 19A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"1.4","upperLimit":"2.0"},{"groupId":"OG001","value":"1.8","lowerLimit":"1.6","upperLimit":"2.2"}]}]},{"title":"Serotype 19F","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","lowerLimit":"2.1","upperLimit":"2.9"},{"groupId":"OG001","value":"2.5","lowerLimit":"2.2","upperLimit":"2.9"}]}]},{"title":"Serotype 23F","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"277"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.7","upperLimit":"1.1"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.8","upperLimit":"1.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone without rMenB+OMV NZ, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The non-inferiority (NI) was to be demonstrated if the lower limit of the 2-sided 98.3% confidence interval (CI) of the between-group ratio of ECL assay GMC is \\>0.5 for the PCV13 Serotype 1 antigen.","paramType":"Group GMC Ratio","paramValue":"1.05","ciPctValue":"98.3","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.90","ciUpperLimit":"1.23","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way Analysis of Variance (ANOVA), accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone without rMenB+OMV NZ, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 98.3% CI for the between-group ratio of ECL assay GMC is \\>0.5 for the PCV13 Serotype 3 antigen.","paramType":"Group GMC Ratio","paramValue":"0.90","ciPctValue":"98.3","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.77","ciUpperLimit":"1.06","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone without rMenB+OMV NZ, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 98.3% CI for the between-group ratio of ECL assay GMC is \\>0.5 for the PCV13 Serotype 4 antigen.","paramType":"Group GMC Ratio","paramValue":"0.98","ciPctValue":"98.3","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.84","ciUpperLimit":"1.15","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone without rMenB+OMV NZ, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 98.3% CI for the between-group ratio of ECL assay GMC is \\>0.5 for the PCV13 Serotype 5 antigen.","paramType":"Group GMC Ratio","paramValue":"1.03","ciPctValue":"98.3","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.86","ciUpperLimit":"1.22","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone without rMenB+OMV NZ, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 98.3% CI for the between-group ratio of ECL assay GMC is \\>0.5 for the PCV13 Serotype 6 antigen.","paramType":"Group GMC Ratio","paramValue":"0.95","ciPctValue":"98.3","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.81","ciUpperLimit":"1.11","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone without rMenB+OMV NZ, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 98.3% CI for the between-group ratio of ECL assay GMC is \\>0.5 for the PCV13 Serotype 6B antigen.","paramType":"Group GMC Ratio","paramValue":"0.80","ciPctValue":"98.3","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.63","ciUpperLimit":"1.02","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone without rMenB+OMV NZ, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 98.3% CI for the between-group ratio of ECL assay GMC is \\>0.5 for the PCV13 Serotype 7F antigen.","paramType":"Group GMC Ratio","paramValue":"0.98","ciPctValue":"98.3","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.85","ciUpperLimit":"1.12","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone without rMenB+OMV NZ, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 98.3% CI for the between-group ratio of ECL assay GMC is \\>0.5 for the PCV13 Serotype 9V antigen.","paramType":"Group GMC Ratio","paramValue":"0.94","ciPctValue":"98.3","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.80","ciUpperLimit":"1.12","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone without rMenB+OMV NZ, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 98.3% CI for the between-group ratio of ECL assay GMC is \\>0.5 for the PCV13 Serotype 14 antigen.","paramType":"Group GMC Ratio","paramValue":"1.01","ciPctValue":"98.3","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.82","ciUpperLimit":"1.24","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone without rMenB+OMV NZ, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 98.3% CI for the between-group ratio of ECL assay GMC is \\>0.5 for the PCV13 Serotype 18C antigen.","paramType":"Group GMC Ratio","paramValue":"1.00","ciPctValue":"98.3","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.85","ciUpperLimit":"1.18","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone without rMenB+OMV NZ, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 98.3% CI for the between-group ratio of ECL assay GMC is \\>0.5 for the PCV13 Serotype 19A antigen.","paramType":"Group GMC Ratio","paramValue":"0.91","ciPctValue":"98.3","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.77","ciUpperLimit":"1.06","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone without rMenB+OMV NZ, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 98.3% CI for the between-group ratio of ECL assay GMC is \\>0.5 for the PCV13 Serotype 19F antigen.","paramType":"Group GMC Ratio","paramValue":"0.99","ciPctValue":"98.3","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.86","ciUpperLimit":"1.14","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone without rMenB+OMV NZ, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 98.3% CI for the between-group ratio of ECL assay GMC is \\>0.5 for the PCV13 Serotype 23F antigen.","paramType":"Group GMC Ratio","paramValue":"0.87","ciPctValue":"98.3","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.73","ciUpperLimit":"1.05","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."}]},{"type":"SECONDARY","title":"Adjusted GMCs of IgG Antibodies Against 13 PCV13 Antigens at 1 Month After the Fourth Vaccination Administered at Day 301","description":"The immune response to PCV13 is evaluated by measuring IgG levels using ECL assay. Adjusted GMCs are assessed for each of the 13 PCV13 antigens at 1 month after the 4th vaccination.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"µg/mL","timeFrame":"At Day 331 (1 month after the fourth vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"classes":[{"title":"Serotype 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"1.5","upperLimit":"2.1"},{"groupId":"OG001","value":"1.8","lowerLimit":"1.6","upperLimit":"2.1"}]}]},{"title":"Serotype 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"239"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.4","upperLimit":"0.6"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.5","upperLimit":"0.6"}]}]},{"title":"Serotype 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"1.2","upperLimit":"1.8"},{"groupId":"OG001","value":"1.7","lowerLimit":"1.4","upperLimit":"2.0"}]}]},{"title":"Serotype 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"1.5","upperLimit":"2.1"},{"groupId":"OG001","value":"1.8","lowerLimit":"1.6","upperLimit":"2.1"}]}]},{"title":"Serotype 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","lowerLimit":"4.4","upperLimit":"6.1"},{"groupId":"OG001","value":"6.0","lowerLimit":"5.2","upperLimit":"7.0"}]}]},{"title":"Serotype 6B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","lowerLimit":"3.9","upperLimit":"5.6"},{"groupId":"OG001","value":"5.4","lowerLimit":"4.6","upperLimit":"6.4"}]}]},{"title":"Serotype 7F","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","lowerLimit":"3.2","upperLimit":"4.4"},{"groupId":"OG001","value":"4.6","lowerLimit":"4.0","upperLimit":"5.3"}]}]},{"title":"Serotype 9V","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"2.0","upperLimit":"2.8"},{"groupId":"OG001","value":"2.6","lowerLimit":"2.2","upperLimit":"3.1"}]}]},{"title":"Serotype 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","lowerLimit":"5.8","upperLimit":"8.4"},{"groupId":"OG001","value":"7.1","lowerLimit":"6.0","upperLimit":"8.4"}]}]},{"title":"Serotype 18C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"1.7","upperLimit":"2.4"},{"groupId":"OG001","value":"2.2","lowerLimit":"1.9","upperLimit":"2.6"}]}]},{"title":"Serotype 19A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"3.8","upperLimit":"5.3"},{"groupId":"OG001","value":"5.5","lowerLimit":"4.7","upperLimit":"6.4"}]}]},{"title":"Serotype 19F","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","lowerLimit":"4.1","upperLimit":"5.7"},{"groupId":"OG001","value":"5.0","lowerLimit":"4.3","upperLimit":"5.9"}]}]},{"title":"Serotype 23F","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"1.5","upperLimit":"2.3"},{"groupId":"OG001","value":"1.9","lowerLimit":"1.6","upperLimit":"2.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group ratio of ECL assay GMCs is \\>0.5 for the PCV13 Serotype 1 antigen.","paramType":"Group GMC Ratio","paramValue":"0.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.82","ciUpperLimit":"1.11","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group ratio of ECL assay GMCs is \\>0.5 for the PCV13 Serotype 3 antigen.","paramType":"Group GMC Ratio","paramValue":"0.90","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.79","ciUpperLimit":"1.03","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group ratio of ECL assay GMCs is \\>0.5 for the PCV13 Serotype 4 antigen.","paramType":"Group GMC Ratio","paramValue":"0.90","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.77","ciUpperLimit":"1.07","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group ratio of ECL assay GMCs is \\>0.5 for the PCV13 Serotype 5 antigen.","paramType":"Group GMC Ratio","paramValue":"0.97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.83","ciUpperLimit":"1.12","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group ratio of ECL assay GMCs is \\>0.5 for the PCV13 Serotype 6 antigen.","paramType":"Group GMC Ratio","paramValue":"0.86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.74","ciUpperLimit":"0.99","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group ratio of ECL assay GMCs is \\>0.5 for the PCV13 Serotype 6B antigen.","paramType":"Group GMC Ratio","paramValue":"0.86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.73","ciUpperLimit":"1.02","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group ratio of ECL assay GMCs is \\>0.5 for the PCV13 Serotype 7F antigen.","paramType":"Group GMC Ratio","paramValue":"0.81","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.70","ciUpperLimit":"0.93","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group ratio of ECL assay GMCs is \\>0.5 for the PCV13 Serotype 9V antigen.","paramType":"Group GMC Ratio","paramValue":"0.90","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.77","ciUpperLimit":"1.06","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group ratio of ECL assay GMCs is \\>0.5 for the PCV13 Serotype 14 antigen.","paramType":"Group GMC Ratio","paramValue":"0.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.83","ciUpperLimit":"1.17","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group ratio of ECL assay GMCs is \\>0.5 for the PCV13 Serotype 18C antigen.","paramType":"Group GMC Ratio","paramValue":"0.89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.76","ciUpperLimit":"1.04","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group ratio of ECL assay GMCs is \\>0.5 for the PCV13 Serotype 19A antigen.","paramType":"Group GMC Ratio","paramValue":"0.82","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.71","ciUpperLimit":"0.95","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group ratio of ECL assay GMCs is \\>0.5 for the PCV13 Serotype 19F antigen.","paramType":"Group GMC Ratio","paramValue":"0.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.83","ciUpperLimit":"1.12","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group ratio of ECL assay GMCs is \\>0.5 for the PCV13 Serotype 23F antigen.","paramType":"Group GMC Ratio","paramValue":"0.97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.82","ciUpperLimit":"1.16","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."}]},{"type":"SECONDARY","title":"Percentage of Participants With Serum Pneumococcal Anti-capsular Polysaccharide IgG >= 0.35 μg/mL","description":"The immune response to PCV13 is evaluated by measuring the percentage of participants with serum IgG concentrations ≥ 0.35 μg/mL for each of the 13 PCV13 antigens at 1 month after the third and fourth vaccinations.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 151 (1 month after the third vaccination) and Day 331 (1 month after the fourth vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"classes":[{"title":"Serotype 1, At Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","lowerLimit":"97.1","upperLimit":"99.9"},{"groupId":"OG001","value":"97.1","lowerLimit":"94.4","upperLimit":"98.7"}]}]},{"title":"Serotype 1, At Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","lowerLimit":"96.2","upperLimit":"99.7"},{"groupId":"OG001","value":"97.1","lowerLimit":"94.1","upperLimit":"98.8"}]}]},{"title":"Serotype 3, At Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"59.8","lowerLimit":"53.4","upperLimit":"66.0"},{"groupId":"OG001","value":"61.5","lowerLimit":"55.5","upperLimit":"67.3"}]}]},{"title":"Serotype 3, At Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"239"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","lowerLimit":"56.9","upperLimit":"69.8"},{"groupId":"OG001","value":"69.5","lowerLimit":"63.2","upperLimit":"75.2"}]}]},{"title":"Serotype 4, At Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.3","lowerLimit":"90.6","upperLimit":"96.8"},{"groupId":"OG001","value":"96.0","lowerLimit":"93.0","upperLimit":"98.0"}]}]},{"title":"Serotype 4, At Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","lowerLimit":"94.9","upperLimit":"99.3"},{"groupId":"OG001","value":"96.7","lowerLimit":"93.5","upperLimit":"98.6"}]}]},{"title":"Serotype 5, At Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.0","lowerLimit":"86.7","upperLimit":"94.3"},{"groupId":"OG001","value":"87.4","lowerLimit":"82.9","upperLimit":"91.1"}]}]},{"title":"Serotype 5, At Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","lowerLimit":"92.5","upperLimit":"98.2"},{"groupId":"OG001","value":"98.8","lowerLimit":"96.4","upperLimit":"99.7"}]}]},{"title":"Serotype 6, At Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","lowerLimit":"97.1","upperLimit":"99.9"},{"groupId":"OG001","value":"99.6","lowerLimit":"98.0","upperLimit":"100"}]}]},{"title":"Serotype 6, At Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"98.4","upperLimit":"100"},{"groupId":"OG001","value":"99.6","lowerLimit":"97.7","upperLimit":"100"}]}]},{"title":"Serotype 6B, At Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","lowerLimit":"85.2","upperLimit":"93.3"},{"groupId":"OG001","value":"92.4","lowerLimit":"88.7","upperLimit":"95.3"}]}]},{"title":"Serotype 6B, At Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"98.4","upperLimit":"100"},{"groupId":"OG001","value":"99.6","lowerLimit":"97.7","upperLimit":"100"}]}]},{"title":"Serotype 7F, At Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","lowerLimit":"97.7","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"98.7","upperLimit":"100"}]}]},{"title":"Serotype 7F, At Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","lowerLimit":"97.5","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"98.5","upperLimit":"100"}]}]},{"title":"Serotype 9V, At Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.1","lowerLimit":"91.6","upperLimit":"97.4"},{"groupId":"OG001","value":"93.2","lowerLimit":"89.5","upperLimit":"95.8"}]}]},{"title":"Serotype 9V, At Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","lowerLimit":"96.1","upperLimit":"99.7"},{"groupId":"OG001","value":"98.8","lowerLimit":"96.4","upperLimit":"99.7"}]}]},{"title":"Serotype 14, At Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","lowerLimit":"95.3","upperLimit":"99.3"},{"groupId":"OG001","value":"98.6","lowerLimit":"96.4","upperLimit":"99.6"}]}]},{"title":"Serotype 14, At Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"98.4","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"98.5","upperLimit":"100"}]}]},{"title":"Serotype 18C, At Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","lowerLimit":"94.7","upperLimit":"99.1"},{"groupId":"OG001","value":"96.8","lowerLimit":"93.9","upperLimit":"98.5"}]}]},{"title":"Serotype 18C, At Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","lowerLimit":"96.8","upperLimit":"99.9"},{"groupId":"OG001","value":"99.2","lowerLimit":"97.0","upperLimit":"99.9"}]}]},{"title":"Serotype 19A, At Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.7","lowerLimit":"93.6","upperLimit":"98.6"},{"groupId":"OG001","value":"98.6","lowerLimit":"96.4","upperLimit":"99.6"}]}]},{"title":"Serotype 19A, At Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"98.4","upperLimit":"100"},{"groupId":"OG001","value":"99.6","lowerLimit":"97.7","upperLimit":"100"}]}]},{"title":"Serotype 19F, At Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"278"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","lowerLimit":"97.7","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"98.7","upperLimit":"100"}]}]},{"title":"Serotype 19F, At Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"98.4","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"98.5","upperLimit":"100"}]}]},{"title":"Serotype 23F, At Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"277"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","lowerLimit":"82.5","upperLimit":"91.2"},{"groupId":"OG001","value":"87.0","lowerLimit":"82.5","upperLimit":"90.7"}]}]},{"title":"Serotype 23F, At Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"240"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","lowerLimit":"94.3","upperLimit":"99.0"},{"groupId":"OG001","value":"97.1","lowerLimit":"94.1","upperLimit":"98.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 1 antigen.","paramType":"Difference in percentage","paramValue":"2.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.38","ciUpperLimit":"4.87","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 1 antigen.","paramType":"Difference in percentage","paramValue":"1.58","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.28","ciUpperLimit":"4.74","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 3 antigen.","paramType":"Difference in percentage","paramValue":"-1.67","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.07","ciUpperLimit":"6.70","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV, compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 3 antigen.","paramType":"Difference in percentage","paramValue":"-5.90","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-14.45","ciUpperLimit":"2.69","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 4 antigen.","paramType":"Difference in percentage","paramValue":"-1.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.87","ciUpperLimit":"1.97","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 4 antigen.","paramType":"Difference in percentage","paramValue":"1.11","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.17","ciUpperLimit":"4.51","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 5 antigen.","paramType":"Difference in percentage","paramValue":"3.57","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.86","ciUpperLimit":"8.96","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 5 antigen.","paramType":"Difference in percentage","paramValue":"-2.75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.33","ciUpperLimit":"0.16","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 6 antigen.","paramType":"Difference in percentage","paramValue":"-0.46","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.62","ciUpperLimit":"1.27","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 6 antigen.","paramType":"Difference in percentage","paramValue":"0.42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.27","ciUpperLimit":"2.33","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 6B antigen.","paramType":"Difference in percentage","paramValue":"-2.69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.86","ciUpperLimit":"2.21","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 6B antigen.","paramType":"Difference in percentage","paramValue":"0.42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.27","ciUpperLimit":"2.33","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 7F antigen.","paramType":"Difference in percentage","paramValue":"-0.41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.29","ciUpperLimit":"0.96","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 7F antigen.","paramType":"Difference in percentage","paramValue":"-0.44","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.48","ciUpperLimit":"1.14","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 9V antigen.","paramType":"Difference in percentage","paramValue":"1.92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.30","ciUpperLimit":"6.12","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 9V antigen.","paramType":"Difference in percentage","paramValue":"-0.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.76","ciUpperLimit":"2.44","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 14 antigen.","paramType":"Difference in percentage","paramValue":"-0.61","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.43","ciUpperLimit":"1.87","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 14 antigen.","paramType":"Difference in percentage","paramValue":"0.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.68","ciUpperLimit":"1.58","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 18C antigen.","paramType":"Difference in percentage","paramValue":"0.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.40","ciUpperLimit":"3.91","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 18C antigen.","paramType":"Difference in percentage","paramValue":"-0.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.44","ciUpperLimit":"2.20","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 19A antigen.","paramType":"Difference in percentage","paramValue":"-1.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.06","ciUpperLimit":"0.83","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 19A antigen.","paramType":"Difference in percentage","paramValue":"0.42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.27","ciUpperLimit":"2.33","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 19F antigen.","paramType":"Difference in percentage","paramValue":"-0.41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.29","ciUpperLimit":"0.96","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 19F antigen.","paramType":"Difference in percentage","paramValue":"0.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.68","ciUpperLimit":"1.58","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 23F antigen.","paramType":"Difference in percentage","paramValue":"0.29","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.62","ciUpperLimit":"6.07","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of PCV13 when administered concomitantly with rMenB+OMV NZ and other RIV compared to PCV13 and other RIV alone, at one month after the fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with IgG ≥ 0.35 µg/mL is \\>-10% for the PCV13 Serotype 23F antigen.","paramType":"Difference in percentage","paramValue":"0.25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.13","ciUpperLimit":"3.58","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."}]},{"type":"SECONDARY","title":"Adjusted GMCs Against 3 Pertussis Antigens (Pertussis Toxin [PT], Pertactin [PRN], Filamentous Hemagglutinin [FHA])","description":"The immune response to DTaP-HBV-IPV (Pediarix) vaccine is evaluated. IgG concentrations for pertussis antigens (PT, FHA, PRN) are measured at 1 month after the third vaccination and are expressed as international units per millilitre (IU/mL).","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"IU/mL","timeFrame":"At Day 151 (1 month after the third vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"470"},{"groupId":"OG001","value":"266"}]}],"classes":[{"title":"PT","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"468"},{"groupId":"OG001","value":"266"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.3","lowerLimit":"45.1","upperLimit":"56.0"},{"groupId":"OG001","value":"59.6","lowerLimit":"53.2","upperLimit":"66.8"}]}]},{"title":"FHA","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"470"},{"groupId":"OG001","value":"266"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"106.7","lowerLimit":"96.4","upperLimit":"118.0"},{"groupId":"OG001","value":"133.1","lowerLimit":"119.5","upperLimit":"148.2"}]}]},{"title":"Pertactin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"470"},{"groupId":"OG001","value":"266"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","lowerLimit":"36.1","upperLimit":"48.1"},{"groupId":"OG001","value":"65.7","lowerLimit":"56.4","upperLimit":"76.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of DTaP-HBV-IPV vaccine when administered concomitantly with rMenB+OMV NZ and PCV13 compared to DTaP-HBV-IPV vaccine concomitantly administered with PCV13 without rMenB+OMV NZ, in terms of PT, FHA and PRN, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group GMC ratio is \\>0.67 for the antigen PT.","paramType":"Group GMC Ratio","paramValue":"0.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.76","ciUpperLimit":"0.94","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of DTaP-HBV-IPV vaccine when administered concomitantly with rMenB+OMV NZ and PCV13 compared to DTaP-HBV-IPV vaccine concomitantly administered with PCV13 without rMenB+OMV NZ, in terms of PT, FHA and PRN, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group GMC ratio is \\>0.67 for the antigen FHA.","paramType":"Group GMC Ratio","paramValue":"0.80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.73","ciUpperLimit":"0.88","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of DTaP-HBV-IPV vaccine when administered concomitantly with rMenB+OMV NZ and PCV13 compared to DTaP-HBV-IPV vaccine concomitantly administered with PCV13 without rMenB+OMV NZ, in terms of PT, FHA and PRN, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group GMC ratio is \\>0.67 for the antigen PRN.","paramType":"Group GMC Ratio","paramValue":"0.63","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.55","ciUpperLimit":"0.73","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."}]},{"type":"SECONDARY","title":"Percentage of Participants With Antibodies Concentrations Against Hepatitis B Surface Antigen (AntiHBsAg) >= 10 mIU/mL","description":"The immune response to DTaP-HBV-IPV vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for Hepatitis B (HepB) antigens are measured at 1 month after the third vaccination.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 151 (1 month after the third vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"138"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.5","upperLimit":"100"},{"groupId":"OG001","value":"99.3","lowerLimit":"96.0","upperLimit":"100"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of DTaP-HBV-IPV vaccine when administered concomitantly with rMenB+OMV NZ and PCV13 compared to DTaP-HBV-IPV vaccine concomitantly administered with PCV13 without rMenB+OMV NZ, in terms of Hep B, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with anti-HBs \\>=10 mIU/mL is \\>-10% for the HBs antigen.","paramType":"Difference in percentage","paramValue":"0.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.83","ciUpperLimit":"4.00","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-diphtheria and Anti-tetanus Antibody Concentrations >= 0.1 IU/mL","description":"The immune response to DTaP-HBV-IPV vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for diphtheria (D) and tetanus (T) were measured at 1 month after the third vaccination.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 151 (1 month after the third vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"143"}]}],"classes":[{"title":"Tetanus Toxoid","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"98.4","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"97.5","upperLimit":"100"}]}]},{"title":"Diphtheria Toxoid","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","lowerLimit":"97.5","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"97.3","upperLimit":"100"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of DTaP-HBV-IPV vaccine when administered concomitantly with rMenB+OMV NZ and PCV13 compared to DTaP-HBV-IPV vaccine concomitantly administered with PCV13 without rMenB+OMV NZ, in terms of D, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with anti-diphtheria toxoid concentrations \\>=0.1 IU/mL is \\>-10%.","paramType":"Difference in percentage","paramValue":"0.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.69","ciUpperLimit":"2.62","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of DTaP-HBV-IPV vaccine when administered concomitantly with rMenB+OMV NZ and PCV13 compared to DTaP-HBV-IPV vaccine concomitantly administered with PCV13 without rMenB+OMV NZ, in terms of T, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with anti-tetanus toxoid concentrations \\>=0.1 IU/mL is \\>-5%.","paramType":"Difference in percentage","paramValue":"-0.45","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.53","ciUpperLimit":"2.30","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-polyribosyl-ribitol Phosphate (PRP) Concentration >= 0.15 µg/mL and >= 1 µg/mL","description":"The immune response to Hib vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for Haemophilus influenzae type b (Hib) are measured at 1 month after the third vaccination.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 151 (1 month after the third vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"347"},{"groupId":"OG001","value":"264"}]}],"classes":[{"title":">= 0.15 µg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"98.3","lowerLimit":"96.3","upperLimit":"99.4"},{"groupId":"OG001","value":"97.7","lowerLimit":"95.1","upperLimit":"99.2"}]}]},{"title":">= 1 µg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"87.0","lowerLimit":"83.0","upperLimit":"90.4"},{"groupId":"OG001","value":"84.1","lowerLimit":"79.1","upperLimit":"88.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of Hib vaccine when administered concomitantly with rMenB+OMV NZ and PCV13 compared to Hib vaccine concomitantly administered with PCV13 without rMenB+OMV NZ, in terms of Hib, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with anti-PRP concentration \\>=0.15 µg/mL is \\>-5%.","paramType":"Difference in percentage","paramValue":"0.54","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.79","ciUpperLimit":"3.32","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."},{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of Hib vaccine when administered concomitantly with rMenB+OMV NZ and PCV13 compared to Hib vaccine concomitantly administered with PCV13 without rMenB+OMV NZ, in terms of Hib, at one month after the third vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the group differences in percentage of participants with anti-PRP concentration \\>=1 µg/mL is \\>-10%.","paramType":"Difference in percentage","paramValue":"2.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.63","ciUpperLimit":"8.78","estimateComment":"The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen."}]},{"type":"SECONDARY","title":"Adjusted GMCs for Anti-measles Antibodies","description":"The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for measles antigens are measured using adjusted GMCs at 1 month after fourth vaccination and are expressed as milli-International Units per milliliter (mIU/mL).","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mIU/mL","timeFrame":"At Day 331 (1 month after the fourth vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"435"},{"groupId":"OG001","value":"235"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"877.3","lowerLimit":"743.7","upperLimit":"1035.0"},{"groupId":"OG001","value":"873.5","lowerLimit":"732.2","upperLimit":"1042.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of MMR vaccine when administered concomitantly with rMenB+OMV NZ and PCV13 compared to MMR vaccine concomitantly administered with PCV13, without rMenB+OMV NZ, at one month after fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group GMC ratio is \\> 0.67 for the antigen \"Measles\".","paramType":"Group GMC Ratio","paramValue":"1.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.86","ciUpperLimit":"1.17","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."}]},{"type":"SECONDARY","title":"Adjusted GMCs for Anti-mumps Antibodies","description":"The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for mumps antigens are measured using adjusted GMCs at 1 month after fourth vaccination.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Arbitrary Units per milliliter (AU/mL)","timeFrame":"At Day 331 (1 month after the fourth vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"435"},{"groupId":"OG001","value":"235"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"744.5","lowerLimit":"628.5","upperLimit":"882.0"},{"groupId":"OG001","value":"856.8","lowerLimit":"715.0","upperLimit":"1026.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of MMR vaccine when administered concomitantly with rMenB+OMV NZ and PCV13 compared to MMR vaccine concomitantly administered with PCV13, without rMenB+OMV NZ, at one month after fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group GMC ratio is \\> 0.67 for the antigen \"Mumps\".","paramType":"Group GMC Ratio","paramValue":"0.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.74","ciUpperLimit":"1.02","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."}]},{"type":"SECONDARY","title":"Adjusted GMCs for Anti-rubella Antibodies","description":"The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for rubella antigens are measured using adjusted GMCs at 1 month after fourth vaccination.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"IU/mL","timeFrame":"At Day 331 (1 month after the fourth vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"432"},{"groupId":"OG001","value":"235"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.7","lowerLimit":"50.0","upperLimit":"66.6"},{"groupId":"OG001","value":"54.0","lowerLimit":"46.3","upperLimit":"63.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of MMR vaccine when administered concomitantly with rMenB+OMV NZ, VV and PCV13 compared to MMR vaccine concomitantly administered with PCV13, without rMenB+OMV NZ, at one month after fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group GMC ratio is \\> 0.67 for the antigen \"Rubella\".","paramType":"Group GMC Ratio","paramValue":"1.07","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.93","ciUpperLimit":"1.22","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."}]},{"type":"SECONDARY","title":"Adjusted GMCs for Anti-Varicella (VV) Antibodies","description":"The immune response to varicella (VV) vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for varicella antigens are measured using GMCs at 1 month after fourth vaccination.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mIU/mL","timeFrame":"At Day 331 (1 month after the fourth vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"437"},{"groupId":"OG001","value":"231"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1283.8","lowerLimit":"1137.4","upperLimit":"1449.2"},{"groupId":"OG001","value":"1208.9","lowerLimit":"1060.5","upperLimit":"1378.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the immunological non-inferiority of VV vaccine when administered concomitantly with rMenB+OMV NZ, MMR and PCV13 compared to VV vaccine concomitantly administered with PCV13, without rMenB+OMV NZ, at one month after fourth vaccination.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The NI was to be demonstrated if the lower limit of the 2-sided 95% CI for the between-group GMC ratio is \\> 0.67 for the antigen \"VZV gE\".","paramType":"Group GMC Ratio","paramValue":"1.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.95","ciUpperLimit":"1.19","estimateComment":"GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects."}]},{"type":"SECONDARY","title":"Percentage of Participants With hSBA Antibody Titers >= 5, >= 8 and >=16 for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)","description":"This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 151 (1 month after the third vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"553"}]}],"classes":[{"title":"M14459 (fHbp), >= 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"537"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","lowerLimit":"89.6","upperLimit":"94.3"}]}]},{"title":"M14459 (fHbp), >= 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"537"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"82.9","lowerLimit":"79.4","upperLimit":"86.0"}]}]},{"title":"M14459 (fHbp), >= 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"537"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","lowerLimit":"46.2","upperLimit":"54.8"}]}]},{"title":"96217 (NadA), >= 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"525"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","lowerLimit":"98.6","upperLimit":"100"}]}]},{"title":"96217 (NadA), >= 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"525"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","lowerLimit":"98.6","upperLimit":"100"}]}]},{"title":"96217 (NadA), >= 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"525"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","lowerLimit":"98.3","upperLimit":"99.9"}]}]},{"title":"NZ98/254 (PorA P1.4), >= 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"547"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.7","lowerLimit":"74.0","upperLimit":"81.1"}]}]},{"title":"NZ98/254 (PorA P1.4), >= 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"547"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.8","lowerLimit":"57.6","upperLimit":"65.9"}]}]},{"title":"NZ98/254 (PorA P1.4), >= 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"547"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","lowerLimit":"27.2","upperLimit":"35.1"}]}]},{"title":"M13520 (NHBA), >= 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"553"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.4","lowerLimit":"56.2","upperLimit":"64.5"}]}]},{"title":"M13520 (NHBA), >= 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"553"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","lowerLimit":"28.5","upperLimit":"36.4"}]}]},{"title":"M13520 (NHBA), >= 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"553"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","lowerLimit":"7.1","upperLimit":"12.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With hSBA Antibody Titers >= 5 and >= 8 for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)","description":"This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 301 (6 months after third vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"540"}]}],"classes":[{"title":"M14459 (fHbp), >= 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"516"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","lowerLimit":"11.6","upperLimit":"17.9"}]}]},{"title":"M14459 (fHbp), >= 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"516"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","lowerLimit":"3.2","upperLimit":"7.1"}]}]},{"title":"96217 (NadA) >= 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","lowerLimit":"96.1","upperLimit":"98.9"}]}]},{"title":"96217 (NadA), >= 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","lowerLimit":"94.4","upperLimit":"97.9"}]}]},{"title":"NZ98/254 (PorA P1.4), >= 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","lowerLimit":"16.8","upperLimit":"23.8"}]}]},{"title":"NZ98/254 (PorA P1.4), >= 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","lowerLimit":"9.6","upperLimit":"15.3"}]}]},{"title":"M13520 (NHBA), >= 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"540"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","lowerLimit":"7.8","upperLimit":"13.1"}]}]},{"title":"M13520 (NHBA) >= 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"540"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","lowerLimit":"4.1","upperLimit":"8.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With hSBA Antibody Titers >= 5 for Each of the Serogroup B Test Strain M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)","description":"This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 331 (1 month after the fourth vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"}]}],"classes":[{"title":"M14459 (fHbp), >= 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.5","lowerLimit":"92.1","upperLimit":"96.4"}]}]},{"title":"96217 (NadA), >= 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"482"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","lowerLimit":"98.5","upperLimit":"99.9"}]}]},{"title":"NZ98/254 (PorA P1.4), >= 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"499"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.6","lowerLimit":"86.6","upperLimit":"92.1"}]}]},{"title":"M13520 (NHBA), >= 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.5","lowerLimit":"88.7","upperLimit":"93.8"}]}]}]},{"type":"SECONDARY","title":"hSBA Geometric Mean Titers (GMTs) Against Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)","description":"This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"At Day 151 (1 month after the third vaccination), Day 301 (6 months after the third vaccination), and Day 331 (1 month after the fourth vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"553"}]}],"classes":[{"title":"M14459 (fHbp), Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"537"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","lowerLimit":"13.7","upperLimit":"16.7"}]}]},{"title":"M14459 (fHbp), Day 301","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"516"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","lowerLimit":"2.8","upperLimit":"3.2"}]}]},{"title":"M14459 (fHbp), Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.3","lowerLimit":"21.3","upperLimit":"27.8"}]}]},{"title":"96217 (NadA), Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"525"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"488.2","lowerLimit":"437.3","upperLimit":"545.0"}]}]},{"title":"96217 (NadA), Day 301","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","lowerLimit":"77.3","upperLimit":"102.7"}]}]},{"title":"96217 (NadA), Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"482"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1349.0","lowerLimit":"1195.3","upperLimit":"1522.5"}]}]},{"title":"NZ98/254 (PorA P1.4), Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"547"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","lowerLimit":"8.9","upperLimit":"11.4"}]}]},{"title":"NZ98/254 (PorA P1.4), Day 301","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"3.5","upperLimit":"4.0"}]}]},{"title":"NZ98/254 (PorA P1.4), Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"499"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.3","lowerLimit":"17.3","upperLimit":"23.7"}]}]},{"title":"M13520 (NHBA), Day 151","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"553"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"5.0","upperLimit":"6.0"}]}]},{"title":"M13520 (NHBA), Day 301","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"540"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"3.3","upperLimit":"3.7"}]}]},{"title":"M13520 (NHBA), Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","lowerLimit":"11.2","upperLimit":"14.4"}]}]}]},{"type":"SECONDARY","title":"hSBA Geometric Mean Ratios (GMRs) Over Pre Fourth Vaccination Against Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)","description":"This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"At Day 331 (1 month after the fourth vaccination) compared to Day 301 (pre-fourth vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"465"}]}],"classes":[{"title":"M14459 (fHbp)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"435"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","lowerLimit":"7.6","upperLimit":"10.0"}]}]},{"title":"96217 (NadA)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"420"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","lowerLimit":"15.1","upperLimit":"20.1"}]}]},{"title":"NZ98/254 (PorA P1.4)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"452"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"4.7","upperLimit":"6.5"}]}]},{"title":"M13520 (NHBA)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"465"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","lowerLimit":"3.4","upperLimit":"4.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With hSBA Antibody Titers >= LLOQ for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)","description":"This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 301 (6 months after the third vaccination) and Day 331 (1 month after the fourth vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"540"}]}],"classes":[{"title":"M14459 (fHbp), Day 301","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"516"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","lowerLimit":"11.6","upperLimit":"17.9"}]}]},{"title":"M14459 (fHbp), Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"492"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.5","lowerLimit":"92.1","upperLimit":"96.4"}]}]},{"title":"96217 (NadA), Day 301","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","lowerLimit":"91.6","upperLimit":"96.0"}]}]},{"title":"96217 (NadA), Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"482"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","lowerLimit":"98.5","upperLimit":"99.9"}]}]},{"title":"M13520 (NHBA), Day 301","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"540"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","lowerLimit":"6.3","upperLimit":"11.2"}]}]},{"title":"M13520 (NHBA), Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"505"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.1","lowerLimit":"82.8","upperLimit":"89.0"}]}]},{"title":"NZ98/254 (PorA P1.4), Day 301","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"531"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","lowerLimit":"14.4","upperLimit":"21.0"}]}]},{"title":"NZ98/254 (PorA P1.4), Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"499"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.6","lowerLimit":"84.4","upperLimit":"90.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With 4-fold Rise in hSBA Titers for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)","description":"A 4-fold rise in hSBA titers is defined as - if pre-vaccination titer \\<Limit of Detection (LOD), then a post-vaccination titer \\>= 4 times the LOD or \\>= LLOQ, whichever is greater; - if pre-vaccination titer is \\>= LOD but \\<LLOQ, then a post-vaccination titer \\>= 4 times the LLOQ; - if pre-vaccination titer is \\>= LLOQ, then a post-vaccination titer \\>= 4 times the pre-vaccination titer, where pre-vaccination titer=pre-4th dose titers (Day 301). This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 331 (1 month after the fourth vaccination) relative to Day 301 (pre-fourth vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"465"}]}],"classes":[{"title":"M14459 (fHbp), Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"435"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.0","lowerLimit":"67.5","upperLimit":"76.1"}]}]},{"title":"96217 (NadA), Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"420"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.8","lowerLimit":"92.2","upperLimit":"96.7"}]}]},{"title":"M13520 (NHBA), Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"465"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","lowerLimit":"31.8","upperLimit":"40.7"}]}]},{"title":"NZ98/254 (PorA P1.4), Day 331","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"452"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.2","lowerLimit":"49.5","upperLimit":"58.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-HBs Antibody Concentrations >= 100 mIU/mL","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 151 (1 month after the third vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"138"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","lowerLimit":"93.3","upperLimit":"99.8"},{"groupId":"OG001","value":"96.4","lowerLimit":"91.7","upperLimit":"98.8"}]}]}]},{"type":"SECONDARY","title":"GMCs for Anti-HBsAg Antibodies","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mIU/mL","timeFrame":"At Day 151 (1 month after the third vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"138"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2201.0","lowerLimit":"1554.7","upperLimit":"3116.0"},{"groupId":"OG001","value":"2404.8","lowerLimit":"1803.1","upperLimit":"3207.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-diphtheria and Anti-tetanus Antibody Concentrations >= 1 IU/mL","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 151 (1 month after the third vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"143"}]}],"classes":[{"title":"Tetanus Toxoid","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.0","lowerLimit":"60.4","upperLimit":"73.1"},{"groupId":"OG001","value":"69.2","lowerLimit":"61.0","upperLimit":"76.7"}]}]},{"title":"Diphtheria Toxoid","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","lowerLimit":"33.5","upperLimit":"46.8"},{"groupId":"OG001","value":"55.1","lowerLimit":"46.4","upperLimit":"63.7"}]}]}]},{"type":"SECONDARY","title":"GMCs for Anti-diphtheria and Anti-tetanus Antibodies","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"IU/mL","timeFrame":"At Day 151 (1 month after the third vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"143"}]}],"classes":[{"title":"Tetanus Toxoid","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"1.3","upperLimit":"1.8"},{"groupId":"OG001","value":"1.6","lowerLimit":"1.3","upperLimit":"1.9"}]}]},{"title":"Diphtheria Toxoid","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.8","upperLimit":"1.1"},{"groupId":"OG001","value":"1.2","lowerLimit":"1.0","upperLimit":"1.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-polio Type 1, 2 and 3 Neutralization Antibody Titers >= 8","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 151 (1 month after the third vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"120"}]}],"classes":[{"title":"Polio 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.4","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"97.0","upperLimit":"100"}]}]},{"title":"Polio 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"116"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","lowerLimit":"94.9","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"96.9","upperLimit":"100"}]}]},{"title":"Polio 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.3","upperLimit":"100"},{"groupId":"OG001","value":"99.1","lowerLimit":"95.1","upperLimit":"100"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroresponse for Anti-Varicella (VV), Anti-measles Virus, Anti-mumps Virus and Anti-rubella Virus Antibodies","description":"Seroresponse is defined as post-vaccination anti-VZV virus, anti-measles virus, anti-mumps virus and anti-rubella virus antibody concentration \\>= a protective threshold among participants who were seronegative (antibody concentration \\< assay cut-off) before vaccination.","populationDescription":"Analysis was performed on the PPS for immunogenicity. Only participants with data available at the specified timepoints were included in this analysis.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 331 (1 month after the fourth vaccination)","groups":[{"id":"OG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301."},{"id":"OG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"364"},{"groupId":"OG001","value":"201"}]}],"classes":[{"title":"Mumps","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"198"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.6","lowerLimit":"77.2","upperLimit":"85.5"},{"groupId":"OG001","value":"85.9","lowerLimit":"80.2","upperLimit":"90.4"}]}]},{"title":"Measles","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"347"},{"groupId":"OG001","value":"191"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.8","lowerLimit":"91.9","upperLimit":"96.9"},{"groupId":"OG001","value":"97.9","lowerLimit":"94.7","upperLimit":"99.4"}]}]},{"title":"Rubella","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"199"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.4","lowerLimit":"82.3","upperLimit":"89.8"},{"groupId":"OG001","value":"83.9","lowerLimit":"78.1","upperLimit":"88.7"}]}]},{"title":"VZV gE","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"364"},{"groupId":"OG001","value":"201"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","lowerLimit":"95.0","upperLimit":"98.7"},{"groupId":"OG001","value":"97.5","lowerLimit":"94.3","upperLimit":"99.2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Solicited AEs: Day 1 to Day 7 post each vaccination, Solicited systemic AEs of salivary gland swelling, fever and rash: Day 1 to Day 30 post fourth vaccination; Unsolicited AEs: Day 1 to Day 30 post each vaccination. All-cause mortality, SAEs, AEs leading to withdrawal, AESIs and MAAEs: For participants not reaching Day 481 by Protocol Amendment 7: first vaccination (Day 1) to Day 481, for participants past Day 481 by the amendment: first vaccination (Day 1) to Day 661","eventGroups":[{"id":"EG000","title":"MenB+PCV Group","description":"Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301.","deathsNumAffected":0,"deathsNumAtRisk":781,"seriousNumAffected":35,"seriousNumAtRisk":781,"otherNumAffected":771,"otherNumAtRisk":781},{"id":"EG001","title":"Placebo+PCV Group","description":"Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301.","deathsNumAffected":0,"deathsNumAtRisk":403,"seriousNumAffected":19,"seriousNumAtRisk":403,"otherNumAffected":389,"otherNumAtRisk":403}],"seriousEvents":[{"term":"Lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Bronchogenic cyst","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"PFAPA syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Serum sickness","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Adenovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Complicated appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Coxsackie viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Picornavirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Respiratory syncytial virus bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Respiratory syncytial virus bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Respiratory syncytial virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Respiratory tract infection viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Rhinovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Near drowning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Skull fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Neuroblastoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Febrile convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Subarachnoid haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Adenoidal hypertrophy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Bronchial hyperreactivity","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Obstructive sleep apnoea syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Tonsillar hypertrophy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":403}]},{"term":"Iron deficiency anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":20,"numAtRisk":781},{"groupId":"EG001","numEvents":23,"numAffected":20,"numAtRisk":403}]},{"term":"Thrombocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Brachycephaly","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Craniofacial deformity","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Dacryostenosis congenital","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Developmental hip dysplasia","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Hydrocele","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Kidney duplex","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Macrocephaly","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Plagiocephaly","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":403}]},{"term":"Strabismus congenital","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Tethered oral tissue","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Cerumen impaction","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Conductive deafness","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Ear disorder","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":781},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":403}]},{"term":"Eustachian tube dysfunction","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Middle ear effusion","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Otorrhoea","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Tympanic membrane perforation","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Astigmatism","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Dacryostenosis acquired","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Eczema eyelids","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Eye discharge","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":403}]},{"term":"Eye movement disorder","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Eye swelling","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":403}]},{"term":"Eyelid oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Eyelid rash","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Ocular hyperaemia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Pseudostrabismus","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Scleral discolouration","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Swelling of eyelid","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Abnormal faeces","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Anal fissure","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Aphthous ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":31,"numAtRisk":781},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":403}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":350,"numAffected":334,"numAtRisk":781},{"groupId":"EG001","numEvents":193,"numAffected":178,"numAtRisk":403}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Faeces discoloured","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Faeces hard","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Food protein-induced enterocolitis syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Frequent bowel movements","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":781},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":403}]},{"term":"Gastrooesophageal reflux in neonate","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Gingival cyst","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Gingival disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Infantile colic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Infantile spitting up","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Mucous stools","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Oral mucosal eruption","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Post-tussive vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Protein-losing gastroenteropathy","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Regurgitation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Retching","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Teething","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":84,"numAffected":75,"numAtRisk":781},{"groupId":"EG001","numEvents":55,"numAffected":46,"numAtRisk":403}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":328,"numAffected":317,"numAtRisk":781},{"groupId":"EG001","numEvents":174,"numAffected":159,"numAtRisk":403}]},{"term":"Vomiting projectile","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Administration site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":460,"numAffected":460,"numAtRisk":781},{"groupId":"EG001","numEvents":170,"numAffected":170,"numAtRisk":403}]},{"term":"Administration site induration","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":480,"numAffected":480,"numAtRisk":781},{"groupId":"EG001","numEvents":180,"numAffected":180,"numAtRisk":403}]},{"term":"Administration site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":582,"numAffected":582,"numAtRisk":781},{"groupId":"EG001","numEvents":201,"numAffected":201,"numAtRisk":403}]},{"term":"Administration site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":322,"numAffected":322,"numAtRisk":781},{"groupId":"EG001","numEvents":122,"numAffected":122,"numAtRisk":403}]},{"term":"Adverse drug reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Adverse food reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Crying","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":433,"numAffected":432,"numAtRisk":781},{"groupId":"EG001","numEvents":163,"numAffected":163,"numAtRisk":403}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Hypothermia","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Induration","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Injection site bruising","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":781},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":403}]},{"term":"Injection site discolouration","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Injection site dryness","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Injection site induration","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Injection site laceration","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Injection site nodule","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Injection site rash","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":6,"numAffected":2,"numAtRisk":403}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Injection site urticaria","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Injury associated with device","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Irritability postvaccinal","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":543,"numAffected":521,"numAtRisk":781},{"groupId":"EG001","numEvents":184,"numAffected":172,"numAtRisk":403}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Swelling face","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Tenderness","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Vaccination site bruising","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Vaccination site irritation","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Food allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Abscess limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Acute sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":403}]},{"term":"Body tinea","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":30,"numAtRisk":781},{"groupId":"EG001","numEvents":16,"numAffected":13,"numAtRisk":403}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Bullous impetigo","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":781},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":403}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Candida nappy rash","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":781},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":403}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Chronic sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":17,"numAtRisk":781},{"groupId":"EG001","numEvents":17,"numAffected":15,"numAtRisk":403}]},{"term":"Conjunctivitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Conjunctivitis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Coxsackie viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Croup infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":24,"numAtRisk":781},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":403}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Dacryocystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Ear infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Erythema infectiosum","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Exanthema subitum","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Eye infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":403}]},{"term":"Folliculitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Fungal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":781},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":403}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Gastrointestinal viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Hand-foot-and-mouth disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":781},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":403}]},{"term":"Impetigo","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":403}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":781},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":403}]},{"term":"Injection site cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Laryngotracheitis obstructive","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Nail infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":40,"numAtRisk":781},{"groupId":"EG001","numEvents":20,"numAffected":18,"numAtRisk":403}]},{"term":"Onychomycosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":781},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":403}]},{"term":"Oral viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Otitis externa","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":55,"numAffected":47,"numAtRisk":781},{"groupId":"EG001","numEvents":37,"numAffected":29,"numAtRisk":403}]},{"term":"Otitis media acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":33,"numAtRisk":781},{"groupId":"EG001","numEvents":28,"numAffected":23,"numAtRisk":403}]},{"term":"Otitis media chronic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Parainfluenzae virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Parvovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Periorbital cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Pertussis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Pharyngitis streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Pustule","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Respiratory syncytial virus bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":403}]},{"term":"Respiratory syncytial virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":781},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":403}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Respiratory tract infection viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Roseola","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Rotavirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":781},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":403}]},{"term":"Skin candida","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":781},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":403}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Suspected COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Tinea cruris","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":149,"numAffected":125,"numAtRisk":781},{"groupId":"EG001","numEvents":79,"numAffected":62,"numAtRisk":403}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":13,"numAtRisk":781},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":403}]},{"term":"Viral pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Viral rash","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":16,"numAtRisk":781},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":403}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Accident at home","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Accidental exposure to product","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Animal bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Animal scratch","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Arthropod bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Corneal abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Eyelid injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Foreign body ingestion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Scar","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Scrotal injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Superficial injury of eye","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Blood lead increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Body temperature decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Body temperature increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Breath sounds abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Cardiac murmur","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Human rhinovirus test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Occult blood positive","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Platelet count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"SARS-CoV-2 test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Serum ferritin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":403}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Breast milk substitute intolerance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Feeding disorder","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Food intolerance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Hypophagia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":544,"numAffected":543,"numAtRisk":781},{"groupId":"EG001","numEvents":217,"numAffected":216,"numAtRisk":403}]},{"term":"Iron deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Milk soy protein intolerance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Weight gain poor","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Acquired plagiocephaly","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Jaw clicking","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Joint noise","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Muscle tightness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Torticollis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Haemangioma of skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Drooling","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Fine motor delay","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Infant irritability","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Movement disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Myoclonus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Nystagmus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Petit mal epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":681,"numAffected":681,"numAtRisk":781},{"groupId":"EG001","numEvents":322,"numAffected":319,"numAtRisk":403}]},{"term":"Speech disorder developmental","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Breath holding","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Dependent personality disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Emotional distress","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":781},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":403}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":738,"numAffected":713,"numAtRisk":781},{"groupId":"EG001","numEvents":345,"numAffected":330,"numAtRisk":403}]},{"term":"Middle insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Selective eating disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Renal hypertrophy","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Single functional kidney","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Epididymal cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Genital labial adhesions","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Genital rash","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Penile adhesion","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Penile cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Penile dermatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Vaginal discharge","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Brief resolved unexplained event","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Bronchial hyperreactivity","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Choking","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":58,"numAffected":51,"numAtRisk":781},{"groupId":"EG001","numEvents":25,"numAffected":20,"numAtRisk":403}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":39,"numAtRisk":781},{"groupId":"EG001","numEvents":19,"numAffected":17,"numAtRisk":403}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Respiration abnormal","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Respiratory disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":781},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":403}]},{"term":"Respiratory symptom","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":31,"numAtRisk":781},{"groupId":"EG001","numEvents":20,"numAffected":17,"numAtRisk":403}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":25,"numAtRisk":781},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":403}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Snoring","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Upper respiratory tract irritation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":781},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":403}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Acne infantile","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Blood blister","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":781},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":403}]},{"term":"Dermatitis atopic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":781},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":403}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Dermatitis diaper","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":41,"numAffected":38,"numAtRisk":781},{"groupId":"EG001","numEvents":25,"numAffected":22,"numAtRisk":403}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":781},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":403}]},{"term":"Ecchymosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":781},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":403}]},{"term":"Eczema infantile","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Ingrowing nail","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Intertrigo","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Miliaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":403}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Perioral dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Post inflammatory pigmentation change","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":224,"numAffected":216,"numAtRisk":781},{"groupId":"EG001","numEvents":117,"numAffected":106,"numAtRisk":403}]},{"term":"Rash erythematous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Rash macular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Rash papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Seborrhoea","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Seborrhoeic dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":403}]},{"term":"Skin discolouration","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Skin fissures","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Skin irritation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Umbilical erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":781},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":403}]},{"term":"Child abuse","organSystem":"Social circumstances","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Cyanosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Lymphoedema","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":403}]},{"term":"Pallor","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]},{"term":"Scalp haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":781},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":403}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","email":"GSKClinicalSupportHD@gsk.com","phone":"866-435-7343"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-12-19","uploadDate":"2025-12-23T07:05","filename":"Prot_000.pdf","size":3270934},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2025-06-26","uploadDate":"2025-12-23T07:05","filename":"SAP_001.pdf","size":702492}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["United Kingdom"],"submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2026-01-16","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D008589","term":"Meningococcal Infections"},{"id":"D008581","term":"Meningitis"},{"id":"D008585","term":"Meningitis, Meningococcal"}],"ancestors":[{"id":"D016870","term":"Neisseriaceae Infections"},{"id":"D016905","term":"Gram-Negative Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"},{"id":"D000090862","term":"Neuroinflammatory Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D016920","term":"Meningitis, Bacterial"},{"id":"D020806","term":"Central Nervous System Bacterial Infections"},{"id":"D002494","term":"Central Nervous System Infections"},{"id":"D002493","term":"Central Nervous System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C570015","term":"4CMenB vaccine"},{"id":"C472675","term":"PEDIARIX"},{"id":"C514867","term":"Hiberix"},{"id":"C492457","term":"RIX4414 vaccine"},{"id":"D022542","term":"Measles-Mumps-Rubella Vaccine"},{"id":"D019433","term":"Chickenpox Vaccine"},{"id":"D000068357","term":"Saline Waters"}],"ancestors":[{"id":"D017778","term":"Vaccines, Combined"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D008458","term":"Measles Vaccine"},{"id":"D014765","term":"Viral Vaccines"},{"id":"D009108","term":"Mumps Vaccine"},{"id":"D012411","term":"Rubella Vaccine"},{"id":"D022283","term":"Herpesvirus Vaccines"},{"id":"D004777","term":"Environment"},{"id":"D055669","term":"Ecological and Environmental Phenomena"},{"id":"D001686","term":"Biological Phenomena"}]}},"hasResults":true}